Compositions and methods for treating galactosemia
Aldose reductase inhibitors like zopolrestat and epalrestat address galactosemia complications by reducing galactitol accumulation, effectively treating and preventing tissue damage and long-term issues in galactosemic patients.
Patent Information
- Application Number
- JP2024135647
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2017-07-28
- Filing Date
- 2024-08-15
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Galactosemia, a metabolic disorder resulting from enzyme deficiencies in the Leloir pathway, leads to galactose and galactose metabolite accumulation, causing tissue damage and long-term complications despite dietary restrictions, with no current treatment or prevention for these complications.
Administering therapeutically effective amounts of aldose reductase inhibitors, such as zopolrestat or epalrestat, to inhibit the conversion of galactose to galactitol, thereby reducing galactitol accumulation and associated pathologies.
Reduces galactitol levels, preventing or treating complications like cataracts, neurological dysfunction, and ovarian insufficiency in galactosemic patients, improving quality of life and reducing long-term health issues.
Smart Images

Figure 2024159794000001_ABST
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Application No. 62 / 538,443, filed July 28, 2017, which is incorporated by reference in its entirety. [Background technology]
[0002] background Galactosemia is a metabolic disorder resulting from a reduced ability or inability to metabolize galactose. The disease is typically caused by the deficiency of one or more enzymes involved in the Leloir pathway, including galactose-1-phosphate uridyl transferase (GALT), galactokinase (GALK) and galactose-6-phosphate epimerase (GALE). Deficiency of one or more of these enzymes leads to the disruption of the Leloir pathway and the accumulation of galactose and certain galactose metabolites, such as galactose 1-phosphate (G1P) and galactonate. In addition, when galactose accumulates, it can become a substrate for aldose reductase (AR), an enzyme in the polyol pathway of glucose metabolism. AR normally catalyzes the reduction of glucose to sorbitol (the first step in the polyol pathway), but when galactose levels are elevated, it can also convert galactose to galactitol. Accumulation of galactose and galactose metabolites can cause damage to the liver, central nervous system (e.g., brain), kidneys, eyes, and other body systems (Quan-Ma et al., Am J Dis Child., 112(5):477-478, 1966).
[0003] Genetic disorders causing galactosemia can be detected using appropriate screening tests (Berry et al., in "Classic Galactosemia and Clinical Variant Galactosemia,” GeneReviews, Roberta A. Pagon, Eds. University of Washington, Seattle; March, 2017). Currently, there is no cure for galactosemia, and the disease is managed primarily through dietary restrictions by eliminating dairy foods and other foods containing galactose or lactose from the diet (Welling et al., “International Clinical Guideline for the Management of Classical Galactosemia: Diagnosis, Treatment, and Follow up,” J Inherit Metab Dis, 40(2):171-176, 2017; Lai et al., IUBMB Life, 61(11):1063-74, 2009). However, even when galactosemia is detected early and managed through strict dietary restrictions, galactose metabolite levels remain high and the majority of patients experience long-term complications, such as speech disorders, cognitive impairment, neurological symptoms, and ovarian failure (Schadewaldt et al., Arch Physiol Biochem.,120(5):228-39,2014; Berry et al., Mol Genet Metab.,81(1):22-30,2004). However, even with strict dietary management, galactosemia patients remain at high risk for complications due to endogenous (or internal) synthesis of galactose in the body. Endogenous galactose production has been shown to be highest in infancy and early childhood, but continues to plateau throughout adolescence and adulthood. Even with perfect dietary compliance, endogenous production of galactose leads to high levels of galactose metabolites in patients, leading to the development of central nervous system complications (cognitive, intellectual, speech and motor dysfunction) as well as long-term complications including ocular cataracts (which can result in partial blindness) and primary ovarian insufficiency (POI) in galactosemia women.
[0004] Type I galactosemia (OMIM#230400), the most common form of galactosemia, is caused by mutations in GALT, the second enzyme in the Leloir pathway. Mutations in GALK cause type II galactosemia (OMIM#230200). Type III galactosemia (OMIM#230350) is caused by mutations in GALE. All three types are autosomal recessive disorders. Further subtypes of galactosemia have been identified based on the degree of enzyme dysfunction (biochemical phenotype), genotype, and the likelihood of developing acute and long-term complications.
[0005] Although the underlying mechanisms of galactosemia pathology are not fully understood, endogenous production of galactose and the resulting metabolic products are thought to be key factors (Welling et al., J Inherit Metab Dis, 40(2):171-176, 2017). Currently, the only treatment for galactosemia is dietary restriction of galactose, and a lifelong galactose-restricted diet is the current standard of care. Although the diet can reverse the acute clinical picture in newborns, it does not prevent the emergence of long-term complications. No single treatment or prevention modality for long-term complications exists. Thus, there is a recognized but unmet need for methods for the treatment and / or management of galactosemia. [Prior art documents] [Non-patent literature]
[0006] [Non-Patent Document 1] Quan-Ma et al., Am J Dis Child.,112(5):477-478,1966 [Non-Patent Document 2] Berry et al., in “Classic Galactosemia and Clinical Variant Galactosemia,” GeneReviews, Roberta A. Pagon, Eds. University of Washington,Seattle;March,2017 [Non-Patent Document 3] Welling et al., “International Clinical Guideline for the Management of Classical Galactosemia: Diagnosis, Treatment, and Follow up,” J Inherit Metab Dis, 40(2):171-176, 2017 [Non-Patent Document 4] Lai et al., IUBMB Life,61(11):1063-74,2009 [Non-Patent Document 5] Schadewaldt et al., Arch Physiol Biochem., 120(5):228-39, 2014 [Non-Patent Document 6] Berry et al., Mol Genet Metab., 81(1):22-30, 2004 [Non-Patent Document 7] Welling et al., J Inherit Metab Dis, 40(2):171-176, 2017 [Brief description of the drawings]
[0007] [Figure 1] FIG. 1 is a graph showing weight gain in wild-type rat pups (GALT+), GALT null rat pups, and GALT null rat pups treated with an aldose reductase inhibitor (ARI) (Compound A), where weight (g) is plotted on the vertical axis and age (days) is plotted on the horizontal axis.
[0008] [Figure 2-1]Figures 2A-2D are charts showing the effect of aldose reductase inhibitors on cataracts in galactosemic rats. Figure 2A shows the results of the qualitative assessment of cataract presence / severity scores (on a scale of 0-3) on day 9 in control (wild type rats treated with Compound A), and GALT null rats treated with placebo or Compound A. A score of 0 indicates no cataract; a score of 1 indicates mild cataract in terms of size and opacity; a score of 2 indicates moderate cataract in terms of size and opacity; and a score of 3 indicates severe cataract in terms of size and opacity. Cataracts were assessed on postnatal day 22. Figure 2B shows the results of the quantitative digital assessment of cataracts on postnatal day 22 in wild type or GALT null rats treated with Compound B or placebo. Figure 2C shows the results of the qualitative assessment of cataracts in wild-type or GALT null rats treated with Compound B or placebo at postnatal day 10. Figure 2D shows the qualitative assessment of cataracts in wild-type or GALT null rats treated with Compound B or placebo at postnatal day 22. The qualitative analysis of Figures 2C and 2D was performed using the same scoring method as Figure 2A. [Figure 2-2]Figures 2A-2D are charts showing the effect of aldose reductase inhibitors on cataracts in galactosemic rats. Figure 2A shows the results of the qualitative assessment of cataract presence / severity scores (on a scale of 0-3) on day 9 in control (wild type rats treated with Compound A), and GALT null rats treated with placebo or Compound A. A score of 0 indicates no cataract; a score of 1 indicates mild cataract in terms of size and opacity; a score of 2 indicates moderate cataract in terms of size and opacity; and a score of 3 indicates severe cataract in terms of size and opacity. Cataracts were assessed on postnatal day 22. Figure 2B shows the results of the quantitative digital assessment of cataracts on postnatal day 22 in wild type or GALT null rats treated with Compound B or placebo. Figure 2C shows the results of the qualitative assessment of cataracts in wild-type or GALT null rats treated with Compound B or placebo at postnatal day 10. Figure 2D shows the qualitative assessment of cataracts in wild-type or GALT null rats treated with Compound B or placebo at postnatal day 22. The qualitative analysis of Figures 2C and 2D was performed using the same scoring method as Figure 2A. [Figure 2-3]Figures 2A-2D are charts showing the effect of aldose reductase inhibitors on cataracts in galactosemic rats. Figure 2A shows the results of the qualitative assessment of cataract presence / severity scores (on a scale of 0-3) on day 9 in control (wild type rats treated with Compound A), and GALT null rats treated with placebo or Compound A. A score of 0 indicates no cataract; a score of 1 indicates mild cataract in terms of size and opacity; a score of 2 indicates moderate cataract in terms of size and opacity; and a score of 3 indicates severe cataract in terms of size and opacity. Cataracts were assessed on postnatal day 22. Figure 2B shows the results of the quantitative digital assessment of cataracts on postnatal day 22 in wild type or GALT null rats treated with Compound B or placebo. Figure 2C shows the results of the qualitative assessment of cataracts in wild-type or GALT null rats treated with Compound B or placebo at postnatal day 10. Figure 2D shows the qualitative assessment of cataracts in wild-type or GALT null rats treated with Compound B or placebo at postnatal day 22. The qualitative analysis of Figures 2C and 2D was performed using the same scoring method as Figure 2A.
[0009] [Figure 3-1] 3A-3C are bar graphs showing levels of the metabolites galactitol, galactose, and galactose 1-phosphate in the liver, brain, or plasma of control (wild-type rats) and GALT null rats treated with placebo or Compound B. Figure 3A shows galactitol levels; Figure 3B shows galactose levels; and Figure 3C shows galactose-1-phosphate (Gal1P) levels. [Figure 3-2] 3A-3C are bar graphs showing levels of the metabolites galactitol, galactose, and galactose 1-phosphate in the liver, brain, or plasma of control (wild-type rats) and GALT null rats treated with placebo or Compound B. Figure 3A shows galactitol levels; Figure 3B shows galactose levels; and Figure 3C shows galactose-1-phosphate (Gal1P) levels. [Figure 3-3]3A-3C are bar graphs showing levels of the metabolites galactitol, galactose, and galactose 1-phosphate in the liver, brain, or plasma of control (wild-type rats) and GALT null rats treated with placebo or Compound B. Figure 3A shows galactitol levels; Figure 3B shows galactose levels; and Figure 3C shows galactose-1-phosphate (Gal1P) levels. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0010] overview The present disclosure relates to a method for treating galactosemia and treating or preventing complications of galactosemia by administering a therapeutically effective amount of an AR inhibitor to a subject in need of such treatment or prevention.Without being bound to any particular theory, it is believed that, as described herein, inhibition of AR can reduce or prevent the accumulation of galactitol and the resulting pathology associated with galactosemia.
[0011] In one example, a method for treating or preventing galactosemia (or a complication of galactosemia) comprises administering a therapeutically effective amount of zopolrestat to a subject in need thereof. In one example, a method for treating or preventing galactosemia (or a complication of galactosemia) comprises administering a therapeutically effective amount of epalrestat to a subject in need thereof. In one example, a method for treating or preventing galactosemia (or a complication of galactosemia) comprises administering a therapeutically effective amount of any one of the compounds of formulas I-VI to a subject in need thereof. In some embodiments, the AR inhibitor administered is not ponalrestat, epalrestat, sorbinil or sorbinol, imirestat, AND-138, CT-112, zopolrestat, zenarestat, BAL-AR18, AD-5467, M-79175, tolrestat, alkonyl, statyl, berberine or SPR-210.
[0012] The subject to be treated according to the methods disclosed herein may have increased alditol levels in blood, urine or intraocular fluid, such as increased galactitol, myoinositol or sorbitol levels in blood, urine or intraocular fluid.The subject to be treated according to the methods disclosed herein may have galactosemia complications or symptoms, including liver cirrhosis, retinopathy, macular edema, ocular cataract, ovarian dysfunction, muscle or nerve dysfunction, retinopathy, neuropathy, cognitive dysfunction, ataxia, convulsions, pseudomotor cerebrii, speech dysfunction, nerve conduction disorder or mental retardation.In another embodiment, the present disclosure relates to a method for treating or preventing galactosemia-related complications in a subject in need of such treatment or prevention, comprising administering a therapeutically effective amount of a pharmaceutical composition comprising an AR inhibitor and a pharmaceutically acceptable carrier. The present disclosure relates to a method of reducing the amount or level of galactitol in a subject having galactosemia, comprising administering to the subject a therapeutically effective amount of an aldose reductase inhibitor.
[0013] The present disclosure relates to methods for treating cataracts comprising administering a therapeutically effective amount of an aldose reductase inhibitor to a subject in need thereof, preferably the subject in need thereof has galactosemia.
[0014] The present disclosure relates to a method for treating or preventing cognitive or neurological dysfunction associated with galactosemia, comprising administering to a subject having galactosemia a therapeutically effective amount of an aldose reductase inhibitor. In an embodiment, the cognitive or neurological dysfunction associated with galactosemia is speech dysfunction. In an embodiment, the cognitive or neurological dysfunction associated with galactosemia is ataxia. In an embodiment, the cognitive or neurological dysfunction associated with galactosemia is cognitive dysfunction. In an embodiment, the cognitive or neurological dysfunction associated with galactosemia is pseudotumor cerebri. In an embodiment, the cognitive or neurological dysfunction associated with galactosemia is spasticity.
[0015] In another embodiment, the present disclosure provides a method of treating or preventing galactosemia in a subject in need thereof, comprising administering a therapeutically effective amount of (a) a first pharmaceutical composition comprising a compound of Formula I-VI and a pharma- ceutically acceptable carrier; and (b) a second pharmaceutical composition comprising alponalrestat, epalrestat, sorbinil or sorbinol, imirestat, AND-138, CT-112, zopolrestat, zenarestat, BAL-AR18, AD-5467, M-79175, tolrestat, alkonyl, statyl, berberine or SPR-210 and a pharma- ceutically acceptable carrier. The present invention relates to a method comprising administering
[0016] In another embodiment, disclosed herein is the use of an AR inhibitor to inhibit the production of alditol (eg, galactitol) for the treatment of galactosemia.
[0017] In another embodiment, disclosed herein is the use of an AR inhibitor for the manufacture of a medicament for treating galactosemia or a clinical manifestation of galactosemia selected from cataracts and primary ovarian insufficiency (POI).
[0018] The present disclosure also relates to the use of an AR inhibitor (e.g., zopolrestat, epalrestat, a compound of any one of Formulas I-VI) for the treatment of galactosemia and / or the treatment and prevention of complications associated with galactosemia.
[0019] The present disclosure also relates to an AR inhibitor (e.g., zopolrestat, epalrestat, any one of the compounds of Formulas I-VI) for the manufacture of a medicament for the treatment of galactosemia and / or the treatment and prevention of complications associated with galactosemia.
[0020] The present disclosure also relates to a pharmaceutical formulation for the treatment of galactosemia and / or the treatment and prevention of complications associated with galactosemia, comprising an AR inhibitor (e.g., zopolrestat, epalrestat, any one of the compounds of Formulae I-VI) as an active ingredient. Detailed Description
[0021] Various aspects are described in more detail below. However, such aspects may be embodied in many different forms and should not be construed as limited to the embodiments set forth herein; rather, these embodiments are provided so that this disclosure will be thorough and complete.
[0022] The present disclosure relates to the use of AR inhibitors for the treatment of galactosemia. The methods described herein are based in part on the inventor's insight into the role of AR activity in the pathophysiology of galactosemia. In healthy subjects, AR primarily catalyzes the reduction of glucose to sorbitol (the first step in the polyol pathway of glucose metabolism). However, in subjects with high levels of galactose due to defects in the Leloir pathway (e.g., due to defects or deficiencies in related enzymes) and / or other reasons (e.g., due to excessive consumption of lactose, diabetes, endogenous production of galactose), the excess galactose is converted to galactitol by AR. Galactitol is converted to sorbitol by the next enzyme in the polyol pathway, sorbitol. Galactitol produced by this mechanism accumulates in cells because it is not a substrate for galactitol dehydrogenase. This accumulation of galactitol causes or contributes to pathophysiological events in galactosemia tissues, such as hyperosmolality, sugar imbalance, oxidative stress, etc. Thus, the present disclosure relates to a method for treating or preventing galactosemia or complications of galactosemia by administering a therapeutically effective amount of an AR inhibitor to a subject in need of such treatment or prevention. Without being bound to any particular theory, it is believed that inhibition of AR can reduce or prevent the pathologies and complications associated with galactitol accumulation and the resulting galactosemia. These complications can be mediated in part through increased synthesis and / or increased accumulation of galactitol (e.g., due to deficiency or deficiency of enzymes of the Leloir pathway, elevated galactose levels, abnormal AR activity, reduced excretion of galactitol from tissues (e.g., due to renal damage)). Inhibition of aldose reductase can reduce the synthesis and accumulation of galactitol in tissues and the resulting pathologies and complications associated with galactosemia. Thus, the present disclosure further relates to the use of galactitol as a biomarker for aldose reductase inhibition, and also for monitoring the onset, progression and manifestations of galactosemia.
[0023] When a range of values is provided in this disclosure, each intervening value between the upper and lower limits of the range, and any other stated or intervening value within the stated range, is intended to be encompassed within the disclosure. For example, if a range of 1 μM to 8 μM is stated, 2 μM, 3 μM, 4 μM, 5 μM, 6 μM, and 7 μM, as well as ranges of values greater than or equal to 1 μM and ranges of values less than or equal to 8 μM are also intended to be expressly disclosed.
[0024] Unless the context clearly dictates otherwise, the singular forms "a," "an," and "the" include plural referents. Thus, for example, reference to "a compound of Formula I" includes a single compound, as well as two or more of the same or different compounds; reference to "an excipient" includes a single excipient, as well as two or more of the same or different excipients, etc.
[0025] The term "about" means a range of plus or minus 10% of the value, unless otherwise indicated in the context of this disclosure or inconsistent with such interpretation, e.g., "about 50" means 45 to 55, "about 25,000" means 22,500 to 27,500, etc. For example, in a list of values such as "about 49, about 50, about 55," "about 50" means a range extending to less than half the interval between the preceding and following values, e.g., from greater than 49.5 to less than 52.5. Furthermore, the phrases "less than about a value" or "greater than about a value" should be understood in light of the definition of the term "about" provided herein.
[0026] In order to provide a complete, concise and clear description of the various embodiments, the present disclosure includes descriptions of various elements, groups of elements, ranges and other elements of the broader disclosure. It is intended that such elements may be combined in various ways to provide further embodiments of the present disclosure. It is also intended that any disclosed feature (e.g., substituents, analogs, compounds, structures, elements), including individual members of any disclosed group, including any subrange or combination of subranges within a group, may be excluded from the present disclosure or embodiments of the present disclosure for any reason.
[0027] Various embodiments of the present disclosure are described in further detail in the following numbered paragraphs. I. Method
[0028] In general, the present disclosure relates to a method for the treatment of galactosemia (or galactosemia complications), comprising administering to a subject in need thereof a therapeutically effective amount of a compound that inhibits aldose reductase activity. The method is particularly useful for treating and / or preventing complications associated with galactosemia. The compound can be any suitable compound that inhibits AR activity, such as a small molecule compound (e.g., having a size of 5 kDa or less), a biological agent (e.g., an inhibitory RNA against aldose reductase), or a combination thereof. Preferably, the AR inhibitor is a small molecule compound. Suitable small molecule AR inhibitors are known in the art and disclosed herein. Small molecule AR inhibitors include ponalrestat, sorbinil, sorbinol, imirestat, AND-138, CT-112, zenarestat, BAL-AR18, AD-5467, M-79175, tolrestat, alkonyl, statyl, berberine, SPR-210, zopolrestat, epalrestat, compounds disclosed in U.S. Patent No. 8,916,563, U.S. Patent No. 9,650,383, and compounds disclosed herein.Preferred AR inhibitors for use in the present invention include zopolrestat, epalrestat, compounds disclosed in U.S. Patent No. 8,916,563, U.S. Patent No. 9,650,383, and compounds disclosed herein.AR inhibitors can be administered in any suitable molecular form, including pharmaceutically acceptable salts, solvates, prodrugs, and compounds that contain stable isotope forms of one or more atoms, such as deuterium, instead of hydrogen.
[0029] In one example, a method for the treatment of galactosemia (or galactosemia complications) comprises administering a therapeutically effective amount of zopolrestat to a subject in need thereof. Thus, the present disclosure provides a method for the treatment of galactosemia and prevention of galactosemia complications in patients with galactosemia, comprising administering a therapeutically effective amount of zopolrestat to a subject in need thereof.
[0030] In one example, a method for treating galactosemia (or galactosemia complications) comprises administering a therapeutically effective amount of epalrestat to a subject in need thereof. Thus, the present disclosure provides a method for treating galactosemia and preventing galactosemia complications in patients with galactosemia, comprising administering a therapeutically effective amount of epalrestat to a subject in need thereof.
[0031] In one example, a method for treating galactosemia (or a galactosemia complication) comprises administering to a subject in need thereof a therapeutically effective amount of an aldose reductase inhibitor, wherein the aldose reductase inhibitor is not ponalrestat, epalrestat, sorbinil or sorbinol, imirestat, AND-138, CT-112, zopolrestat, zenarestat, BAL-AR18, AD-5467, M-79175, tolrestat, alkonyl, statyl, berberine or SPR-210.
[0032] In one example, a method for the treatment of galactosemia (or galactosemia complications) comprises administering to a subject in need thereof a therapeutically effective amount of a compound of any one of formulas I-VI. Accordingly, the present disclosure provides a method for the treatment of galactosemia and prevention of galactosemia complications in a patient with galactosemia, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of any one of formulas I-VI. In a particular example, the compound administered is compound A, or the compound administered is compound B.
[0033] As used herein, the term "treat" refers to curative or palliative (e.g., controlling or alleviating a disease or disease symptom) treatment, which ameliorates the symptoms, clinical signs, and underlying pathology of galactosemia in a manner that improves or stabilizes the subject's condition. The term "preventing" within the context of the present methods may include preventing, reducing, arresting or slowing the progression of galactosemia. The term "preventing" within the context of the present methods may refer to, for example, prophylactic treatment of an individual with galactosemia, such as preventing complications (e.g., symptoms and clinical signs) associated with galactosemia. For example, a family history or predisposition to diabetes may indicate that a subject is at risk for galactosemia and related complications. Thus, the methods may be used to treat galactosemia, treat complications (e.g., symptoms and clinical signs) of galactosemia, and / or treat and prevent complications (e.g., symptoms and clinical signs) of galactosemia.
[0034] As used herein, a "therapeutically effective amount" is an amount of a compound sufficient to achieve a desired therapeutic effect under the conditions of administration, such as an amount that reduces or ameliorates the severity and / or duration of galactosemia or one or more of its clinical signs (e.g., cataracts or primary ovarian insufficiency (POI)), prevents the progression of a condition or symptom associated with galactosemia, or enhances or otherwise improves the therapeutic effect of another treatment for the treatment or management of galactosemia (e.g., hormone therapy in the case of POI, or surgery in the case of cataracts). A therapeutically effective amount may be an amount that reduces, and preferably normalizes, the amount or level of galactose or galactose metabolites, particularly galactitol, in the subject being treated. The actual amount to be administered can be determined by a clinician of ordinary skill, based on, for example, the subject's age, weight, sex, general health and drug tolerance, the severity of the disease, the selected dosage form, the route of administration, and other factors. Typically, the amount of AR inhibitor administered is about 0.5 to about 60 mg / kg body weight / day, for example, about 1.0 to 10 mg / kg.
[0035] In some examples of the implementation of the methods disclosed herein, a therapeutically effective amount is an amount sufficient to reduce intracellular aldose reductase activity by at least about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, about 99% or more, for example about 100% (e.g., compared to pre-treatment level). A therapeutically effective amount can be an amount that reduces intracellular galactitol level by at least about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, about 99% or more, for example about 100% (e.g., compared to pre-treatment level). A therapeutically effective amount can be an amount that reduces plasma galactitol concentration to less than 200 μM, particularly less than 100 μM, particularly less than 50 μM, preferably less than 10 μM in a human subject with galactosemia. Plasma galactitol levels are elevated in untreated classical galactosemia patients (120-500 μmol / l) compared to controls (0.08-0.86 μmol / l). (Jakobs et al., Eur J Pediatr., 154(7 Suppl 2):S50-2, 1995). A therapeutically effective amount may be sufficient to restore physiological attributes that are diminished in galactosemia, such as reduced visual acuity in cataract subjects, or reduced estrogen levels in patients with POI. A therapeutically effective amount of an aldose reductase inhibitor may be sufficient to normalize galactitol levels in tissues (e.g., liver galactitol levels, brain galactitol levels) or blood (plasma).
[0036] A "subject" can be any animal, particularly a mammal, including but not limited to a human, a domestic animal, such as a feline or canine subject, a livestock animal, such as but not limited to a cow, horse, goat, sheep, bird and pig subject, a wild animal (whether wild or zoo), a research or experimental animal, such as a mouse, rat, rabbit, goat, sheep, pig, dog, cat, etc., a bird, such as a chicken, turkey, songbird, etc. Preferably, a "subject" is a human who is predisposed to galactosemia (due to a genetic abnormality) or has been diagnosed with galactosemia. Typically, a human subject to be treated using the methods disclosed herein is diagnosed with galactosemia at birth by enzymatic or genetic screening and has a deficiency of GALT activity, GALK activity or GALE activity.
[0037] The present disclosure also relates to the prevention or treatment of at least one clinical characteristic or complication of galactosemia in a subject. Representative clinical characteristics or complications that may be present in children, adolescents or adults include, for example, liver dysfunction, susceptibility to infections, growth retardation, cataracts, retinopathy, neuropsychological and ovarian problems. For example, the present disclosure relates to the treatment of at least one characteristic of galactosemia subjects selected from jaundice (incidence: 74% of subjects), vomiting (47% of subjects), hepatomegaly (43% of subjects), failure to thrive (29% of subjects), poor feeding (23% of subjects), fatigue (16% of subjects), diarrhea (12% of subjects), sepsis (10% of subjects), more specifically E. coli sepsis (76% of sepsis), coagulopathy, ascites, convulsions, hepatomegaly, hypotension, edema, complete fontanelle, encephalopathy, and excessive bruising or bleeding, primary ovarian insufficiency and premature ovarian failure (POF). In addition, galactosemia patients may have low bone density. Preferably, the clinical features are lens cataract, retinopathy, or ovarian dysfunction (e.g., primary ovarian insufficiency (POI) or premature ovarian failure (POF)). See Berry et al., “Classic Galactosemia and Clinical Variant Galactosemia,” in GeneReviews, Pagon RA, Adam MP, Ardinger HH, et al., Eds. University of Washington, Seattle, 2017.
[0038] Even if the disease is diagnosed early and managed with galactose-restricted diet, patients with galactosemia may experience long-term neurological and cognitive complications.These complications are various and include below average IQ, executive dysfunction, tremor, ataxia, dysarthria, apraxia of speech, depression and anxiety.Therefore, the further preferred clinical features of galactosemia that can be treated or prevented using the methods described herein are central nervous system dysfunction, including neurological and cognitive dysfunction, for example speech dysfunction (e.g., speech delay or disorder), ataxia, convulsion, pseudotumor cerebri and cognitive dysfunction (e.g., low IQ (IQ less than about 85)).
[0039] In certain aspects, the present disclosure relates to a method for the treatment of clinical features or complications of galactosemia comprising administering to a subject in need thereof a therapeutically effective amount of zopolrestat.
[0040] In one example, the disclosure relates to a method for the treatment of clinical features or complications of galactosemia, comprising administering a therapeutically effective amount of epalrestat to a subject in need thereof.
[0041] In one example, the disclosure relates to a method for treating clinical features or complications of galactosemia, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of any one of Formulas I-VI.
[0042] In embodiments, the clinical feature or complication of galactosemia to be treated or prevented is retinopathy or cataract. Presenile cataract is a common complication in patients with galactosemia, and in certain embodiments, the method is a method for treating cataract. Cataracts can be subcapsular cataracts, which occur at the back of the lens, nuclear cataracts, which form in the center (nucleus) of the lens, and cortical (spoke-like) cataracts, which affect the lens cortex. The method is also useful in treating cataracts that have been operated on or are undergoing operation, cataracts that occur after surgical removal of an existing opacified lens, i.e., secondary cataracts, retinal detachment and retinal detachment repair surgery, cataracts associated with eye or head trauma, cataracts associated with tumors, cataracts associated with exposure to radiation, and cataracts associated with glucotoxicity. The method is also useful in treating systemic disorders, such as, but not limited to, cataracts caused by galactosemia. It is useful in the prophylactic treatment of internal organs.
[0043] In an embodiment, the clinical characteristics or complications of galactosemia that should be treated or prevented are the long-term neurological and cognitive complications of galactosemia.Even if the disease is diagnosed early and managed with a galactose-restricted diet, patients with galactosemia may experience long-term neurological and cognitive complications.These complications are various and include below average IQ, impaired executive function, tremor, ataxia, dysarthria, apraxia of speech, depression and anxiety.
[0044] In an embodiment, the clinical feature or complication of galactosemia to be treated or prevented is primary ovarian insufficiency (POI) or premature ovarian failure (POF), or symptoms associated therewith. The method comprises administering to a subject in need thereof a compound of the present disclosure or a composition containing the compound. POI is characterized by dysfunctional ovaries (e.g., inability to produce estrogen and other hormones important to reproductive health). Galactosemia is one of the few known causes of POI, and nearly all women with galactosemia will have or develop POI at some point in their lives. Women with POI may be more likely to develop the bone disease osteoporosis or have heart problems, and POI may also cause infertility. See Fridovich-Keil et al., J Inherit Metab Dis.34(2):357-366,2011. Symptoms or features associated with POI include, for example, delayed onset of periods, abrupt cessation or interruption of periods, breast abnormalities, hot flashes, emotional disturbances such as mood swings or irritability, vaginal dryness and / or poor sleep.
[0045] In some embodiments, the present disclosure relates to a method for reducing the amount or level of galactitol in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of a compound that inhibits aldose reductase activity. The method can be used to reduce galactitol in tissues, such as liver, brain, eye, retina, and / or circulation (e.g., blood or plasma) and / or urine. Preferably, galactitol levels are normalized. In patients with galactosemia, galactose levels may be elevated, and preferably, the method of reducing galactitol does not cause further elevation of galactose levels. The normal amount or level of galactitol is the amount or level present in a healthy subject not in a restricted diet situation. Such normal amounts or levels are well known and are shown in Table 1.
[0046] In embodiments, the clinical feature or complication of galactosemia to be treated or prevented is retinopathy or cataract. Presenile cataract is a common complication in patients with galactosemia, and in certain embodiments, the method is a method for treating cataract. Cataract can be subcapsular cataract, which occurs in the posterior part of the lens, nuclear cataract, which forms in the center (nucleus) of the lens, and cortical (spoke-like) cataract, which affects the lens cortex. The method is also useful in the treatment of cataracts that have been operated on or are undergoing operation, cataracts that occur after surgical removal of an existing opacified lens, i.e., secondary cataracts, retinal detachment and retinal detachment repair surgery, cataracts associated with eye or head trauma, cataracts associated with tumors, cataracts associated with exposure to radiation, and cataracts associated with glucotoxicity. The method is also useful in the prophylactic treatment of systemic disorders, such as, but not limited to, cataracts caused by galactosemia.
[0047] In certain aspects, the present disclosure relates to a method for the treatment or prevention of cataracts comprising administering to a subject in need thereof a therapeutically effective amount of zopolrestat.
[0048] In one example, the present disclosure relates to a method for treating or preventing cataracts, The method includes administering to the subject a therapeutically effective amount of epalrestat.
[0049] In one example, the disclosure relates to a method for the treatment or prevention of cataracts, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of any one of Formulas I-VI. In a particular example, the compound administered is Compound A, or the compound administered is Compound B.
[0050] Preferably, the patient in need of therapy for the treatment or prevention of cataracts has galactosemia.
[0051] In an embodiment, the clinical characteristics or complications of galactosemia that should be treated or prevented are the long-term neurological and cognitive complications of galactosemia.Even if the disease is diagnosed early and managed with a galactose-restricted diet, patients with galactosemia may experience long-term neurological and cognitive complications.These complications are various and include below average IQ, impaired executive function, tremor, ataxia, dysarthria, apraxia of speech, depression and anxiety.
[0052] In certain aspects, the present disclosure relates to a method for the treatment or prevention of neurological and cognitive dysfunction associated with galactosemia, comprising administering a therapeutically effective amount of zopolrestat to a subject with galactosemia. In certain embodiments, the neurological or cognitive dysfunction associated with galactosemia is a speech dysfunction, such as speech delay or language disorder. In certain embodiments, the neurological or cognitive dysfunction associated with galactosemia is ataxia. In certain embodiments, the neurological or cognitive dysfunction associated with galactosemia is a cognitive dysfunction, such as low IQ. In certain embodiments, the neurological or cognitive dysfunction associated with galactosemia is pseudotumor cerebri. In certain embodiments, the neurological or cognitive dysfunction associated with galactosemia is a convulsion.
[0053] In one example, the present disclosure relates to a method for the treatment or prevention of neurological and cognitive dysfunction associated with galactosemia, comprising administering a therapeutically effective amount of epalrestat to a subject with galactosemia. In certain embodiments, the neurological or cognitive dysfunction associated with galactosemia is a speech dysfunction, such as speech delay or language disorder. In certain embodiments, the neurological or cognitive dysfunction associated with galactosemia is ataxia. In certain embodiments, the neurological or cognitive dysfunction associated with galactosemia is a cognitive dysfunction, such as low IQ. In certain embodiments, the neurological or cognitive dysfunction associated with galactosemia is pseudotumor cerebri. In certain embodiments, the neurological or cognitive dysfunction associated with galactosemia is a convulsion.
[0054] In one example, the disclosure relates to a method for the treatment or prevention of neurological and cognitive dysfunction associated with galactosemia, comprising administering to a subject having galactosemia a therapeutically effective amount of a compound of any one of formulas I-VI. In a particular example, the administered compound is Compound A, or the administered compound is Compound B. In certain embodiments, the neurological or cognitive dysfunction associated with galactosemia is a speech dysfunction, e.g., speech delay or language disorder. In certain embodiments, the neurological or cognitive dysfunction associated with galactosemia is ataxia. In certain embodiments, the neurological or cognitive dysfunction associated with galactosemia is a cognitive dysfunction, e.g., low IQ. In certain embodiments, the neurological or cognitive dysfunction associated with galactosemia is pseudotumor cerebri. In certain embodiments, the neurological or cognitive dysfunction associated with galactosemia is a convulsion.
[0055] In an embodiment, the clinical feature or complication of galactosemia to be treated or prevented is primary ovarian insufficiency (POI) or premature ovarian failure (POF), or symptoms associated therewith. The method comprises administering to a subject in need thereof a compound of the present disclosure or a composition containing the compound. POI is characterized by dysfunctional ovaries (e.g., inability to produce estrogen and other hormones important to reproductive health). Galactosemia is one of the few known causes of POI, and nearly all women with galactosemia will have or develop POI at some point in their lives. Women with POI may be more likely to develop the bone disease osteoporosis or have heart problems, and POI may cause infertility. See Fridovich-Keil et al., J Inherit Metab Dis.34(2):357-366,2011. Symptoms or features associated with POI include, for example, delayed onset of periods, abrupt cessation or interruption of periods, breast abnormalities, hot flashes, emotional disturbances such as mood swings or irritability, vaginal dryness and / or poor sleep.
[0056] In certain aspects, the present disclosure relates to a method for the treatment or prevention of POI or POF, comprising administering a therapeutically effective amount of zopolrestat to a subject with galactosemia.
[0057] In one example, the disclosure relates to a method for the treatment or prevention of POI or POF, comprising administering a therapeutically effective amount of epalrestat to a subject with galactosemia.
[0058] In one example, the disclosure relates to a method for treating or preventing POI or POF, comprising administering to a subject with galactosemia a therapeutically effective amount of a compound of any one of Formulas I-VI. In a particular example, the compound administered is Compound A, or the compound administered is Compound B.
[0059] In some embodiments, the present disclosure relates to a method for reducing the amount or level of galactitol in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of a compound that inhibits aldose reductase activity. The method can be used to reduce galactitol in tissues, such as liver, brain, eye, retina, and / or circulation (e.g., blood or plasma) and / or urine. Preferably, galactitol levels are normalized. In patients with galactosemia, galactose levels may be elevated, and preferably, the method of reducing galactitol does not cause further elevation of galactose levels. The normal amount or level of galactitol is the amount or level present in a healthy subject not in a restricted diet situation. Such normal amounts or levels are well known and are shown in Table 1. [Table 1]
[0060] In certain aspects, the present disclosure relates to a method for reducing, and preferably normalizing, the amount or level of galactitol in a subject having galactosemia, comprising administering to a subject in need thereof a therapeutically effective amount of zopolrestat.
[0061] In one example, the present disclosure relates to a method for reducing, and preferably normalizing, the amount or level of galactitol in a subject having galactosemia, comprising administering a therapeutically effective amount of epalrestat to a subject in need thereof.
[0062] In one example, the disclosure relates to a method for reducing, and preferably normalizing, the amount or level of galactitol in a subject having galactosemia, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of any one of Formulas I-VI. In a particular example, the compound administered is Compound A, or the compound administered is Compound B.
[0063] In some embodiments, the methods are carried out by administering a single dose or administration (e.g., as a single injection or depot) of a formulation comprising one or more AR inhibitors. Alternatively, the methods include administering to a subject in need thereof a formulation adapted for administration for about 2 to about 28 days, or about 7 to about 10 days, or about 7 to about 15 days, or more. In some embodiments, the method is performed by administering a formulation adapted for chronic administration. In still other embodiments, the method is performed by administering a formulation adapted for administration over weeks, months, years, or decades. In still other embodiments, the method is performed by administering a formulation adapted for administration over weeks. In still other embodiments, the method is performed by administering a formulation adapted for administration over months. In still other embodiments, the method is performed by administering a formulation adapted for administration over years. In still other embodiments, the method is performed by administering a formulation adapted for administration over decades. II. AR Inhibitors
[0064] Suitable small molecule AR inhibitors are known in the art and disclosed herein.Small molecule AR inhibitors include ponalrestat, sorbinil, sorbinol, imirestat, AND-138, CT-112, zenarestat, BAL-AR18, AD-5467, M-79175, tolrestat, alkonyl, statyl, berberine, SPR-210, zopolrestat, epalrestat, compounds disclosed in U.S. Patent No. 8,916,563, U.S. Patent No. 9,650,383, WO 2012 / 009553, and compounds disclosed herein.Preferred AR inhibitors for use in the present invention include zopolrestat, epalrestat, compounds disclosed in U.S. Patent No. 8,916,563, U.S. Patent No. 9,650,383, WO 2017 / 038505, and compounds disclosed herein. The disclosures of U.S. Pat. No. 8,916,563, U.S. Pat. No. 9,650,383, WO 2012 / 009553 and WO 2017 / 038505, the disclosures of which are incorporated by reference in their entireties, disclose compounds suitable for use in the methods described herein. AR Inhibitors of Formula I and II
[0065] In one example, the AR inhibitor is a compound of formula (I) [ka] or a pharma- ceutically acceptable salt, prodrug, or solvate thereof;
[0066] During the ceremony,
[0067] R 1 is H, (C1-C6)-alkyl, (C1-C6)-hydroxyalkyl or (C1-C6)-aminoalkyl;
[0068] X 1 is N or CR 3 and;
[0069] X 2 is N or CR4 and;
[0070] X 3 is N or CR 5 and;
[0071] X 4 is N or CR 6 where X 1 , X 2 , X 3 or X 4 Two or three of are N;
[0072] Y is a bond, C=O, C=S, C=NH or C=N(C1-C4)-alkyl;
[0073] Z is [ka] and;
[0074] A 1 is NR 11 , O, S or CH2;
[0075] A 2 is N or CH;
[0076] A 3 is NR 11 , O or S;
[0077] R 3 ~R 10 are independently hydrogen, halogen, cyano, acyl, haloalkyl, haloalkoxy, haloalkylthio, trifluoroacetyl, (C-C)-alkyl, (C-C)-alkoxy, (C-C)-alkylthio, (C-C)-alkylsulfinyl or (C-C)-alkylsulfonyl; or R 3 ~R 6 or R 7 ~R 10 are both (C1-C4)-alkylenedioxy; and
[0078] R 11 is hydrogen, C1-C4 alkyl or C(O)O-(C1-C4)-alkyl.
[0079] Z [ka] or Z is [ka] The specification that
[0080] Z [ka] If
[0081] The compound of formula (I) [ka] Inclusive of
[0082] Z [ka] If
[0083] The compound of formula (I) [ka] It will be appreciated by those skilled in the art that the present invention is intended to encompass the
[0084] In certain embodiments, R 1 is hydrogen or (C-C)-alkyl. In certain embodiments, R 1 is hydrogen. In certain embodiments, R 1 is (C1-C6)-alkyl. In certain embodiments, R 1 is tert-butyl.
[0085] In certain embodiments, R 3 ~R 10 is independently hydrogen, halogen, or haloalkyl. In certain embodiments, R 3 ~R 10 is independently hydrogen, halogen, or trihaloalkyl.
[0086] In certain embodiments, R 3 ~R 6 is hydrogen.
[0087] In certain embodiments, R 7 ~R 10 is independently hydrogen, halogen, or haloalkyl. In certain embodiments, R 7 ~R 10 is independently hydrogen, halogen, or trihaloalkyl.
[0088] In certain embodiments, R 7 and R 10 is hydrogen.
[0089] In certain embodiments, R 8 is hydrogen, halogen or haloalkyl. In this state, R 8 is hydrogen. In certain embodiments, R 8 is halogen. In certain embodiments, R 8 is haloalkyl.
[0090] In certain embodiments, R 9 is hydrogen, halogen, or haloalkyl. In certain embodiments, R 9 is hydrogen. In certain embodiments, R 9 is halogen. In certain embodiments, R 9 is haloalkyl.
[0091] In certain embodiments, Y is C=O, C=S, C=NH or C=N(C1-C4)-alkyl. In certain embodiments, Y is C=O or C=S. In certain embodiments, Y is C=O. In certain embodiments, Y is C=S. In certain embodiments, Y is C=NH or C=N(C1-C4)-alkyl.
[0092] In certain embodiments, A 1 is NR 11 , S or CH2. In certain embodiments, A 1 is NR 11 or O. In certain embodiments, A 1 is NR 11 or S. In certain embodiments, A 1 is NR 11 In certain embodiments, A 1 is O. In certain embodiments, A 1 is S.
[0093] In certain embodiments, A 2 is N or CH. In certain embodiments, A 1 is N. In certain embodiments, A 1 is CH.
[0094] In certain embodiments, A 3 is O or S. In certain embodiments, A 3 is O. In certain embodiments, A 3 is S.
[0095] In certain embodiments, X 1 and X 4 is nitrogen.
[0096] In certain embodiments, X 1 and X 2 is nitrogen.
[0097] In certain embodiments, X 1 and X 3 is nitrogen.
[0098] In certain embodiments, X 2 and X 3 is nitrogen.
[0099] In certain embodiments, X 2 and X 4 is nitrogen.
[0100] In certain embodiments, X 3 and X 4 is nitrogen.
[0101] In certain embodiments, Z is [ka] It is.
[0102] In certain embodiments, Z is [ka] It is.
[0103] In certain embodiments, R 1 is hydrogen or (C1-C6)-alkyl;
[0104] X 1 and X 4 is N;
[0105] X 2 is CR 4 and;
[0106] X 3 is CR 5 and;
[0107] Y is C=O;
[0108] Z is [ka] and;
[0109] A 1is NR 11 , O or S;
[0110] A 2 is N;
[0111] A 3 is O or S;
[0112] R 4 and R 5 is hydrogen;
[0113] R 7 ~R 10 are independently hydrogen, halogen, cyano, acyl, haloalkyl, haloalkoxy, haloalkylthio, (C-C)-alkyl, (C-C)-alkoxy, (C-C)-alkylthio, (C-C)-alkylsulfinyl or (C-C)-alkylsulfonyl; and
[0114] R 11 is hydrogen, C1-C4 alkyl or C(O)O-(C1-C4)-alkyl.
[0115] In certain embodiments, R 1 is hydrogen or tert-butyl;
[0116] X 1 and X 4 is N;
[0117] X 2 is CR 4 and;
[0118] X 3 is CR 5 and;
[0119] Y is C=O;
[0120] Z is [ka] and;
[0121] A 1 is NR 11 , O or S;
[0122] A 2 is N;
[0123] A 3 is O or S;
[0124] R 4 and R 5 is hydrogen;
[0125] R 7 ~R 10 is independently hydrogen, halogen or haloalkyl; and
[0126] R 11 is hydrogen, (C1-C4)-alkyl or C(O)O-tert-butyl.
[0127] In certain embodiments, R 1 is hydrogen or tert-butyl;
[0128] X 1 and X 4 is N;
[0129] X 2 is CH;
[0130] X 3 is CH;
[0131] Y is C=O;
[0132] Z is [ka] and;
[0133] A 1 is NR 11 , O or S;
[0134] A 2 is N;
[0135] A 3 is O or S;
[0136] R 7 , R 8 and R 10 is independently hydrogen, halogen, or haloalkyl;
[0137] R 9 is halogen or haloalkyl; and
[0138] R 11 is hydrogen or methyl.
[0139] In certain embodiments, R 1 is hydrogen or tert-butyl;
[0140] X 1 and X 4 is N;
[0141] X 2 is CH;
[0142] X 3 is CH;
[0143] Y is C=O;
[0144] Z is [ka] and;
[0145] A 1 is NR 11 , O or S;
[0146] A 2 is N;
[0147] A 3 is O or S;
[0148] R 7 , R 8 and R 10 is independently hydrogen, halogen, or haloalkyl;
[0149] R 9 is chlorine or trifluoromethyl; and
[0150] R 11 is hydrogen or methyl.
[0151] In certain embodiments, the AR inhibitor is a compound of formula (II):
[0152] [ka] or a pharma- ceutically acceptable salt or solvate thereof;
[0153] In the formula, R 1 , R 7 -R 9 and Y are as described in formula I, preferably R 1 is hydrogen or (C1-C6)-alkyl and Y is C=O. Exemplary compounds of formula II include the following and salts thereof: [ka]
[0154] Compound of Formula III
[0155] The AR inhibitor is a compound of formula (III)
[0156] [ka] or a pharma- ceutically acceptable salt, prodrug, or solvate thereof,
[0157] During the ceremony,
[0158] R1 CO2R 2 or CO2 - X + and;
[0159] R 2 is H, (C1-C6)-alkyl, (C1-C6)-hydroxyalkyl or (C1-C6)-aminoalkyl;
[0160] X 1 is H or a halogen;
[0161] X 2 is H or a halogen;
[0162] Y is a bond, C=O, C=S, C=NH or C=N(C1-C4)-alkyl;
[0163] Z is [ka] and;
[0164] A 1 is NR 7 , O, S or CH2;
[0165] A 2 is N or CH;
[0166] A 3 is NR 7 , O or S;
[0167] R 3 ~R 6 are independently hydrogen, halogen, cyano, acyl, haloalkyl, haloalkoxy, haloalkylthio, trifluoroacetyl, (C1-C4)-alkyl, (C1-C4)-alkoxy, (C1-C4)-alkylthio, (C1-C4)-alkylsulfinyl or (C1-C4)-alkylsulfonyl;
[0168] R 7is hydrogen, C1-C4 alkyl or C(O)O-(C1-C4)-alkyl; and
[0169] X + is the counter ion.
[0170] Z
[0171]
[0172] [ka] or Z is [ka] The specification that Z is
[0173] [ka] then the compound of formula (III) is [ka] It is understood that Z includes [ka] When the compound of formula (I) is [ka] It will be appreciated by those skilled in the art that the term "common" refers to the term "common" as used herein.
[0174] In certain embodiments, R 1 CO2R 2 or CO2 - X + In certain embodiments, R 1 CO2R 2 In certain embodiments, R 1 CO2 - X + It is.
[0175] In certain embodiments, R 2 is hydrogen or (C-C)-alkyl. In certain embodiments, R 2 is hydrogen or (C-C)-alkyl. In certain embodiments, R 2 is hydrogen or (C-C)-alkyl. In certain embodiments, R 2 is hydrogen, methyl, or ethyl. In certain embodiments, R 2 is hydrogen or methyl. In certain embodiments, R 2 is methyl or ethyl. In certain embodiments, R 2 is methyl. In certain embodiments, R 2 is hydrogen. In certain embodiments, R 2 is (C1-C6)-alkyl. In certain embodiments, R 2 is (C1-C6)-n-alkyl. In certain embodiments, R 2 is (C1-C2)-alkyl. In certain embodiments, R 2 is (C1-C3)-alkyl. In certain embodiments, R 2 is (C1-C4)-alkyl. In certain embodiments, R 2 is tert-butyl.
[0176] In certain embodiments, R 3 ~R 6 are independently hydrogen, halogen, cyano, acyl, haloalkyl, haloalkoxy, haloalkylthio, trifluoroacetyl, (C1-C4)-alkyl, (C1-C4)-alkoxy, (C1-C4)-alkylthio, (C1-C4)-alkylsulfinyl or (C1-C4)-alkylsulfonyl.
[0177] In certain embodiments, R 3 ~R 6 is independently hydrogen, halogen, or haloalkyl. In certain embodiments, R 3 ~R 6 is independently hydrogen, halogen, or trihaloalkyl.
[0178] In certain embodiments, R 3 and R 6 is hydrogen. In certain embodiments, R 3 , R 5 and R 6 is hydrogen.
[0179] In certain embodiments, R 4 is hydrogen, halogen, or haloalkyl. In certain embodiments, R 4 is hydrogen. In certain embodiments, R 4 is halogen. In certain embodiments, R 4 is haloalkyl. In certain embodiments, R 4 is CF3.
[0180] In certain embodiments, R 3 ~R 6 is hydrogen. In certain embodiments, R 3 , R 5 , R 6 is hydrogen, and R 4 is halogen or haloalkyl. In certain embodiments, R 3 , R 5 , R 6 is hydrogen, and R 4 is haloalkyl. In certain embodiments, R 3 , R 5 , R 6 is hydrogen, and R 4 is CF3. In certain embodiments, R 3 , R 5 , R 6 is hydrogen, and R 4 is halogen. In certain embodiments, R 3 , R 5 , R 6 is hydrogen R 4 is F. In certain embodiments, R 3 , R 5 , R 6 is hydrogen, and R 4 is Cl.
[0181] In certain embodiments, Y is C=O, C=S, C=NH or C=N(C1-C4)-alkyl. In certain embodiments, Y is C=O or C=S. In certain embodiments, Y is C=O. In certain embodiments, Y is C=S. In certain embodiments, Y is C=NH or C=N(C1-C4)-alkyl.
[0182] In certain embodiments, A 1 is NR 7 , O, S or CH2. In certain embodiments, A 1 is NR 7 , O or S. In certain embodiments, A 1 is NR 7 , S or CH2. In certain embodiments, A 1 is NR 7 or O. In certain embodiments, A 1 is NR 7 or S. In certain embodiments, A 1 is NR 7 In certain embodiments, A 1 is O. In certain embodiments, A 1 is S.
[0183] In certain embodiments, A 2 is N or CH. In certain embodiments, A 2 is N. In certain embodiments, A 2 is CH.
[0184] In certain embodiments, A 3 is NR 7 , O or S. In certain embodiments, A 3 is O. In certain embodiments, A 3 is S. In certain embodiments, A 3 is NR 7 It is.
[0185] In certain embodiments, X 1 and X 2 is hydrogen.
[0186] In certain embodiments, X 1 and X 2 is a halogen. In certain embodiments, X 1 and X 2 is Cl.
[0187] In certain embodiments, X 1 and X 2 is independently hydrogen or halogen. In certain embodiments, X 1 is hydrogen, and X 2 is Cl. In certain embodiments, X 1 is Cl, and X 2 is hydrogen.
[0188] In certain embodiments, Z is [ka] It is.
[0189] In certain embodiments, Z is [ka] It is.
[0190] In certain embodiments, R 7 is hydrogen, C1-C4 alkyl, or C(O)O-(C1-C4)-alkyl. In certain embodiments, R 7 is hydrogen. In certain embodiments, R 7 is C1-C4 alkyl. In certain embodiments, R 7 is C1-C3 alkyl. In certain embodiments, R 7 is C1-C2 alkyl. In certain embodiments, R 7 is C-C-alkyl. In certain embodiments, R 7 is C-C-alkyl. In certain embodiments, R 7 is C(O)O-(C1-C4)-alkyl. In certain embodiments, R 7 is C(O)O-(C1-C3)-alkyl. In certain embodiments, R7 is C(O)O-(C1-C2)-alkyl. In certain embodiments, R 7 is C(O)O-(C1-C4)-n-alkyl. In certain embodiments, R 7 is C(O)O-(C1-C3)-n-alkyl.
[0191] In certain embodiments, R 1 CO2R 2 and;
[0192] R 2 is H or (C1-C6)-alkyl;
[0193] X 1 is H;
[0194] X 2 is H;
[0195] Y is C=O;
[0196] Z is [ka] and;
[0197] A 1 is NR 7 , O or S;
[0198] A 2 is N;
[0199] A 3 is O or S;
[0200] R 3 ~R 6 are independently hydrogen, halogen, cyano, acyl, haloalkyl, haloalkoxy, haloalkylthio, trifluoroacetyl, (C-C)-alkyl, (C-C)-alkoxy, (C-C)-alkylthio, (C-C)-alkylsulfinyl or (C-C)-alkylsulfonyl; and
[0201] R 7 is hydrogen, C1-C4 alkyl or C(O)O-(C1-C4)-alkyl.
[0202] In certain embodiments, R 1 CO2R 2 and;
[0203] R 2 is H or tert-butyl;
[0204] X 1 is H;
[0205] X 2 is H;
[0206] Y is C=O;
[0207] Z is [ka] and;
[0208] A 1 is NR 7 , O or S;
[0209] A 2 is N;
[0210] A 3 is O or S;
[0211] R 6 ~R 6 are independently hydrogen, halogen, haloalkyl; and
[0212] R 7 is hydrogen, C1-C4 alkyl or C(O)O-(C1-C4)-alkyl.
[0213] In certain embodiments, R 1 CO2R 2 and;
[0214] R 2 is H or tert-butyl;
[0215] X 1 is H;
[0216] X 2 is H;
[0217] Y is C=O;
[0218] Z is [ka] and;
[0219] A 1 is NR 7 , O or S;
[0220] A 2 is N;
[0221] A 3 is O or S;
[0222] R 3 , R 5 and R 6 is hydrogen;
[0223] R 4 is hydrogen, halogen or haloalkyl; and
[0224] R 7 is hydrogen, C1-C4 alkyl or C(O)O-(C1-C4)-alkyl.
[0225] In certain embodiments, R 1 CO2R 2 and;
[0226] R 2 is H or (C1-C6)-alkyl;
[0227] X1 is a halogen;
[0228] X 2 is a halogen;
[0229] Y is C=O;
[0230] Z is [ka] and;
[0231] A 1 is NR 7 , O or S;
[0232] A 2 is N;
[0233] A 3 is O or S;
[0234] R 3 ~R 6 are independently hydrogen, halogen, cyano, acyl, haloalkyl, haloalkoxy, haloalkylthio, trifluoroacetyl, (C-C)-alkyl, (C-C)-alkoxy, (C-C)-alkylthio, (C-C)-alkylsulfinyl or (C-C)-alkylsulfonyl; and
[0235] R 7 is hydrogen, C1-C4 alkyl or C(O)O-(C1-C4)-alkyl.
[0236] In certain embodiments, R 1 CO2R 2 and;
[0237] R 2 is H or tert-butyl;
[0238] X 1 is a halogen;
[0239] X 2 is a halogen;
[0240] Y is C=O;
[0241] Z is [ka] and;
[0242] A 1 is NR 7 , O or S;
[0243] A 2 is N;
[0244] A 3 is O or S;
[0245] R 3 ~R 6 are independently hydrogen, halogen, haloalkyl; and
[0246] R 7 is hydrogen, C1-C4 alkyl or C(O)O-(C1-C4)-alkyl.
[0247] In certain embodiments, R 1 CO2R 2 and;
[0248] R 2 is H or tert-butyl;
[0249] X 1 is Cl;
[0250] X 2 is Cl;
[0251] Y is C=O;
[0252] Z is [ka] and;
[0253] A 1 is NR 7 , O or S;
[0254] A 2 is N;
[0255] A 3 is O or S;
[0256] R 3 ~R 6 are independently hydrogen, halogen, haloalkyl; and
[0257] R 7 is hydrogen, C1-C4 alkyl or C(O)O-(C1-C4)-alkyl.
[0258] In certain embodiments, R 1 CO2R 2 and;
[0259] R 2 is H or tert-butyl;
[0260] X 1 is Cl;
[0261] X 2 is Cl;
[0262] Y is C=O;
[0263] Z is [ka] and;
[0264] A 1 is NR 7 , O or S;
[0265] A 2 is N;
[0266] A 3 is O or S;
[0267] R 3 , R 5 and R 6 is hydrogen;
[0268] R 4 is hydrogen, halogen or haloalkyl; and
[0269] R 7 is hydrogen, C1-C4 alkyl or C(O)O-(C1-C4)-alkyl.
[0270] In certain embodiments, the compound of formula (III) is [ka] [ka] is selected from the group consisting of:
[0271] In certain embodiments, the compound of formula (I) is [ka] or a pharma- ceutically acceptable salt thereof.
[0272] In certain embodiments, the compound of formula (I) is [ka] or a pharma- ceutically acceptable salt thereof. Compounds of Formula IV, V and VI
[0273] The AR inhibitor is a compound of formula (IV)
[0274] [ka] or a pharma- ceutically acceptable salt or solvate thereof,
[0275] During the ceremony,
[0276] X 1 is H or a halogen;
[0277] X 2 is H or a halogen;
[0278] Y is a bond, C=O, C=S, C=NH or C=N(C1-C4)-alkyl;
[0279] Z 1 and Z 2 is independently selected from the group consisting of hydroxy, alkoxy, aryloxy, or Z 1 and Z 2 along with the boron atoms to which they are attached,
[0280] [ka] Forming
[0281] Where:
[0282] X is a substituted or unsubstituted C2-C5 alkylene;
[0283] Z is [ka] and;
[0284] A 1 is NR 7 , O, S or CH2;
[0285] A 2 is N or CH;
[0286] A 3 is NR 7 , O or S;
[0287] R 3 ~R 6 are independently hydrogen, halogen, cyano, acyl, haloalkyl, haloalkoxy, haloalkylthio, trifluoroacetyl, (C-C)-alkyl, (C-C)-alkoxy, (C-C)-alkylthio, (C-C)-alkylsulfinyl or (C-C)-alkylsulfonyl; and
[0288] R 7 is hydrogen, C1-C4 alkyl or C(O)O-(C1-C4)-alkyl.
[0289] Suitable substituents on a C2-C5 alkylene include one or more alkyl, alkoxy, aryl, aryloxy, halo, haloalkyl, haloalkoxy, and haloalkylthio. A preferred substituted C2-C5 alkylene is substituted ethylene. A more preferred substituted C2-C5 alkylene is -C(CH3)2C(CH3)2-.
[0290] Z
[0291] [ka] or Z is [ka] The specification that Z is [ka] then the compound of formula (IV) is [ka] is understood to include;
[0292] Z [ka] then the compound of formula (IV) is [ka] It will be appreciated by those skilled in the art that the term "common" refers to the term "common" as used herein.
[0293] During the ceremony,
[0294] Z 1 and Z 2 is independently selected from the group consisting of hydroxy, alkoxy, aryloxy, or Z 1 and Z 2 along with the boron atoms to which they are attached,
[0295] [ka] Forming
[0296] Where:
[0297] X is a substituted or unsubstituted C2-C5 alkylene.
[0298] In certain embodiments, R of formula (IV) 3 ~R 6 are independently hydrogen, halogen, cyano, acyl, haloalkyl, haloalkoxy, haloalkylthio, trifluoroacetyl, (C1-C4)-alkyl, (C1-C4)-alkoxy, (C1-C4)-alkylthio, (C1-C4)-alkylsulfinyl or (C1-C4)-alkylsulfonyl.
[0299] In certain embodiments, R of formula (IV) 3 ~R 6 is independently hydrogen, halogen, or haloalkyl. In certain embodiments, R 3 ~R 6 is independently hydrogen, halogen, or trihaloalkyl.
[0300] In certain embodiments, R of formula (IV)3 and R 6 is hydrogen. In certain embodiments, R 3 , R 5 and R 6 is hydrogen.
[0301] In certain embodiments, R of formula (IV) 4 is hydrogen, halogen, or haloalkyl. In certain embodiments, R 4 is hydrogen. In certain embodiments, R 4 is a halogen. In certain embodiments, R 4 is haloalkyl. In certain embodiments, R 4 is CF3.
[0302] In certain embodiments, R of formula (IV) 3 ~R 6 is hydrogen. In certain embodiments, R 3 , R 5 , R 6 is hydrogen, and R 4 is halogen or haloalkyl. In certain embodiments, R 3 , R 5 , R 6 is hydrogen, and R 4 is haloalkyl. In certain embodiments, R 3 , R 5 , R 6 is hydrogen, and R 4 is CF3. In certain embodiments, R 3 , R 5 , R 6 is hydrogen, and R 4 is halogen. In certain embodiments, R 3 , R 5 , R 6 is hydrogen, and R 4 is F. In certain embodiments, R 3 , R 5 , R 6 is hydrogen, and R 4 is Cl.
[0303] In certain embodiments, Y in formula (IV) is C=O, C=S, C=NH or C=N(C1-C4)-alkyl. In certain embodiments, Y is C=O or C=S. In certain embodiments, Y is C=O. In certain embodiments, Y is C=S. In certain embodiments, Y is C=NH or C=N(C1-C4)-alkyl.
[0304] In certain embodiments, A of formula (IV) 1 is NR 7 , O, S or CH2. In certain embodiments, A 1 is NR 7 , O or S. In certain embodiments, A 1 is NR 7 , S or CH2. In certain embodiments, A 1 is NR 7 or O. In certain embodiments, A 1 is NR 7 or S. In certain embodiments, A 1 is NR 7 In certain embodiments, A 1 is O. In certain embodiments, A 1 is S.
[0305] In certain embodiments, A of formula (IV) 2 is N or CH. In certain embodiments, A 2 is N. In certain embodiments, A 2 is CH.
[0306] In certain embodiments, A of formula (IV) 3 is NR 7 , O or S. In certain embodiments, A 3 is O. In certain embodiments, A in formula (IV) 3 is S. In certain embodiments, A 3 is NR 7 It is.
[0307] In certain embodiments, X in formula (IV) 1 and X 2 is hydrogen.
[0308] In certain embodiments, X in formula (IV) 1 and X 2 is a halogen. In certain embodiments, X 1 and X 2 is Cl.
[0309] In certain embodiments, X in formula (IV) 1 and X 2 is independently hydrogen or halogen. In certain embodiments, X 1 is hydrogen and X 2 is Cl. In certain embodiments, X 1 is Cl and X 2 is hydrogen.
[0310] In certain embodiments, Z in formula (IV) is [ka] It is.
[0311] In certain embodiments, Z in formula (IV) is [ka] It is.
[0312] In certain embodiments, R of formula (IV) 7 is hydrogen, C1-C4 alkyl, or C(O)O-(C1-C4)-alkyl. In certain embodiments, R 7 is hydrogen. In certain embodiments, R 7 is C1-C4 alkyl. In certain embodiments, R 7 is C1-C3 alkyl. In certain embodiments, R 7 is C1-C2 alkyl. In certain embodiments, R 7 is C-C-alkyl. In certain embodiments, R 7 is C-C-alkyl. In certain embodiments, R 7 is C(O)O-(C1-C4)-alkyl. In certain embodiments, R7 is C(O)O-(C1-C3)-alkyl. In certain embodiments, R 7 is C(O)O-(C1-C2)-alkyl. In certain embodiments, R 7 is C(O)O-(C1-C4)-n-alkyl. In certain embodiments, R 7 is C(O)O-(C1-C3)-n-alkyl.
[0313] In certain embodiments, the compound of formula (IV) is
[0314] [ka]
[0315] or a pharma- ceutically acceptable salt, prodrug or solvate thereof;
[0316] During the ceremony,
[0317] Z 1 and Z 2 is independently selected from the group consisting of hydroxy, alkoxy, aryloxy, or Z 1 and Z 2 along with the boron atoms to which they are attached,
[0318] [ka] Forming
[0319] Where:
[0320] X is a substituted or unsubstituted C2-C5 alkylene.
[0321] In certain embodiments, the compound of formula (IV) is
[0322] [ka]
[0323] or a pharma- ceutically acceptable salt, prodrug or solvate thereof;
[0324] During the ceremony,
[0325] Z 1 and Z 2 is independently selected from the group consisting of hydroxy, alkoxy, aryloxy, or Z 1 and Z 2 along with the boron atoms to which they are attached,
[0326] [ka] Forming
[0327] Where:
[0328] X is a substituted or unsubstituted C2-C5 alkylene.
[0329] In certain embodiments, the compound of formula (IV) is
[0330] [ka]
[0331] or a pharma- ceutically acceptable salt, prodrug or solvate thereof;
[0332] During the ceremony,
[0333] Z 1 and Z 2 is independently selected from the group consisting of hydroxy, alkoxy, aryloxy, or Z 1 and Z 2 along with the boron atoms to which they are attached,
[0334] [ka] Forming
[0335] Where:
[0336] X is a substituted or unsubstituted C2-C5 alkylene.
[0337] In certain embodiments, the compound of formula (IV) is
[0338] [ka]
[0339] [ka]
[0340] [ka]
[0341] or a pharma- ceutically acceptable salt, prodrug or solvate thereof;
[0342] During the ceremony,
[0343] Z 1 and Z 2 is independently selected from the group consisting of hydroxy, alkoxy, aryloxy, or Z 1 and Z 2 along with the boron atoms to which they are attached,
[0344] [ka] Forming
[0345] Where:
[0346] X is a substituted or unsubstituted C2-C5 alkylene.
[0347] In another embodiment, the aldose reductase inhibitor is a compound of formula (V)
[0348] [ka]
[0349] or a pharma- ceutically acceptable salt, prodrug or solvate thereof;
[0350] During the ceremony,
[0351] X 3 is N or CR 8 and;
[0352] X 4 is N or CR 9 and;
[0353] X 5 is N or CR 10 and;
[0354] X 6 is N or CR 11 where X 3 , X 4 , X 5 or X 6 Two or three of are N;
[0355] Z 1 and Z 2 is independently selected from the group consisting of hydroxy, alkoxy, aryloxy, or Z 1 and Z 2 along with the boron atoms to which they are attached,
[0356] [ka] Forming
[0357] Where:
[0358] X is a substituted or unsubstituted C2-C5 alkylene;
[0359] Z3 teeth [ka] and;
[0360] A 4 is NR 16 , O, S or CH2;
[0361] A 5 is N or CH;
[0362] A 6 is NR 16 , O or S;
[0363] R 8 ~R 15 are independently hydrogen, halogen, cyano, acyl, haloalkyl, haloalkoxy, haloalkylthio, trifluoroacetyl, (C-C)-alkyl, (C-C)-alkoxy, (C-C)-alkylthio, (C-C)-alkylsulfinyl or (C-C)-alkylsulfonyl; or R 8 ~R 11 or R 12 ~R 15 are both (C1-C4)-alkylenedioxy; and
[0364] R 16 is hydrogen, C1-C4 alkyl or C(O)O-(C1-C4)-alkyl.
[0365] Suitable substituents on the C2-C5 alkylene include one or more of alkyl, alkoxy, aryl, aryloxy, halo, haloalkyl, haloalkoxy, and haloalkylthio. A preferred substituted C2-C5 alkylene is substituted ethylene. A more preferred substituted C2-C5 alkylene is -C(CH3)2C(CH3)2-.
[0366] Z
[0367] [ka] or Z is [ka] The specification that Z is [ka] then the compound of formula (V) is [ka] It is understood that Z includes [ka] then the compound of formula (V) is [ka] It will be appreciated by those skilled in the art that the term "common" refers to the term "common" as used herein.
[0368] In some compounds of formula V, R 8 ~R 15 are independently hydrogen, halogen or haloalkyl, e.g., R 8 ~R 15 is independently hydrogen, halogen, or trihaloalkyl (e.g., -CF3).
[0369] In other compounds of formula V, R 8 ~R 11 is hydrogen.
[0370] In certain embodiments of compounds of formula V, R 12 ~R 15 are independently hydrogen, halogen or haloalkyl, e.g., R 12 ~R 15 is independently hydrogen, halogen, or trihaloalkyl (e.g., -CF3).
[0371] In certain embodiments, R of formula (V) 12and R 15 is hydrogen.
[0372] In certain embodiments, R of formula (V) 13 is hydrogen, halogen, or haloalkyl. In certain embodiments, R 13 is hydrogen. In certain embodiments, R 13 is halogen. In certain embodiments, R 13 is haloalkyl.
[0373] In certain embodiments, R of formula (V) 14 is hydrogen, halogen, or haloalkyl. In certain embodiments, R 14 is hydrogen. In certain embodiments, R 14 is halogen. In certain embodiments, R 14 is haloalkyl.
[0374] In certain embodiments, Y of formula (V) is C=O, C=S, C=NH or C=N(C1-C4)-alkyl. In certain embodiments, Y is C=O or C=S. In certain embodiments, Y is C=O. In certain embodiments, Y is C=S. In certain embodiments, Y is C=NH or C=N(C1-C4)-alkyl.
[0375] In certain embodiments, A of formula (V) 4 is NR 16 , S or CH2. In certain embodiments, A 4 is NR 16 or O. In certain embodiments, A 4 is NR 16 or S. In certain embodiments, A 4 is NR 16 In certain embodiments, A 4 is O. In certain embodiments, A 4 is S.
[0376] In certain embodiments, A of formula (V) 5 is N or CH. In certain embodiments, A 4is N. In certain embodiments, A 4 is CH.
[0377] In certain embodiments, A of formula (V) 6 is O or S. In certain embodiments, A 6 is O. In certain embodiments, A 6 is S.
[0378] In certain embodiments, X in formula (V) 3 and X 6 is nitrogen.
[0379] In certain embodiments, X in formula (V) 3 and X 4 is nitrogen.
[0380] In certain embodiments, X in formula (V) 3 and X 5 is nitrogen.
[0381] In certain embodiments, X in formula (V) 4 and X 5 is nitrogen.
[0382] In certain embodiments, X in formula (V) 4 and X 6 is nitrogen.
[0383] In certain embodiments, X in formula (V) 5 and X 6 is nitrogen.
[0384] In certain embodiments, Z of formula (V) 3 teeth [ka] It is.
[0385] In certain embodiments, Z in formula (V) 3 teeth [ka] It is.
[0386] In some embodiments, the compound of formula (V) is
[0387] [ka]
[0388] or a pharma- ceutically acceptable salt, prodrug or solvate thereof;
[0389] During the ceremony,
[0390] R 14 is hydrogen, halogen or trihaloalkyl (e.g., -CF3); and
[0391] Z 1 and Z 2 is independently selected from the group consisting of hydroxy, alkoxy, and aryloxy. Selected or Z 1 and Z 2 along with the boron atoms to which they are attached,
[0392] [ka] Forming
[0393] Where:
[0394] X is a substituted or unsubstituted C2-C5 alkylene.
[0395] In an embodiment, the compound of formula (V) is
[0396] [ka]
[0397] [ka]
[0398] [ka]
[0399] or a pharma- ceutically acceptable salt, prodrug or solvate thereof.
[0400] In one embodiment, the aldose reductase inhibitor is a compound of formula (VI)
[0401] [ka]
[0402] or a pharma- ceutically acceptable salt, prodrug or solvate thereof;
[0403] During the ceremony,
[0404] Z 1 and Z 2 is independently selected from the group consisting of hydroxy, alkoxy, aryloxy, or Z 1 and Z 2 along with the boron atoms to which they are attached,
[0405]
[0406] [ka] Forming
[0407] Where:
[0408] X is a substituted or unsubstituted C2-C5 alkylene.
[0409] In one embodiment, the aldose reductase inhibitor of formula (VI) is
[0410] [ka]
[0411] or a pharma- ceutically acceptable salt, prodrug or solvate thereof.
[0412] In one embodiment, the AH inhibitor of formula (VI) is
[0413] [ka]
[0414] or a pharma- ceutically acceptable salt, prodrug or solvate thereof.
[0415] As used herein, unless otherwise indicated, the term "alkyl" refers to a monovalent aliphatic hydrocarbon radical having straight-chain, branched-chain, monocyclic or polycyclic moieties, or combinations thereof, optionally substituted on one or more carbons of the straight-chain, branched-chain, monocyclic or polycyclic moieties, or combinations thereof, with one or more substituents at each carbon, wherein the one or more substituents are independently selected from the group consisting of C1-C 10 Examples of "alkyl" groups include methyl, ethyl, propyl, isopropyl, butyl, iso-butyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, norbornyl, and the like.
[0416] As used herein, the term "halogen" or "halo-" means chlorine (Cl), fluorine (F), iodine (I) or bromine (Br).
[0417] As used herein, the term "acyl" is used in a broad sense to designate a radical of the type RCO-, where R represents an organic radical which may be a substituted or unsubstituted, saturated or unsaturated alkyl, aralkyl, aryl, alicyclic or heterocyclic radical; or, according to a different definition, the term "acyl" is used broadly to designate the monovalent radical which remains when the OH group of a carboxyl radical is removed from a molecule of carboxylic acid.
[0418] The term "alkoxy" is used to designate a group of formula -OR, where R is an alkyl group optionally containing substituents such as halogens. Preferably, the term "alkoxy" is used to designate an alkoxy having an alkyl group of 1 to 6 carbon atoms. Most preferably, the term "alkoxy" is used to designate an alkoxy having an alkyl group of 1 to 3 carbon atoms, such as methoxy or ethoxy.
[0419] The term "cycloalkyl group" is used herein to identify a cycloalkyl group having from 3 to 6 carbon atoms, preferably cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
[0420] As used herein, the term "solvate" means a compound or a pharma- ceutically acceptable salt thereof, wherein molecules of a suitable solvent are incorporated into the crystal lattice. Physiologically acceptable at the dosages given. Examples of suitable solvents are ethanol, water, etc. When water is the solvent, the molecule is referred to as a "hydrate."
[0421] "Prodrug" refers to an agent that is converted to a parent drug in vivo. Prodrugs are often useful because in some cases they are easier to administer than the parent drug. They are, for example, bioavailable by oral administration, whereas the parent drug is less bioavailable or not bioavailable at all. Prodrugs also have improved solubility in pharmaceutical compositions than the parent drug. For example, the compound bears a protecting group that is split by hydrolysis in body fluids, such as the bloodstream, to release the active compound, or is oxidized or reduced in body fluids to release the compound. The term "prodrug" can be applied to such functional groups, for example, acidic functional groups of the compound of formula I. Prodrugs can be constructed of structures in which the acidic group is protected, for example, as an ester or amide. Further examples of prodrugs are discussed herein. See also Alexander et al. (J.Med.Chem.1988,31,318), which is incorporated by reference. Examples of prodrugs include, but are not limited to, derivatives and metabolites of compounds that contain a biohydrolyzable moiety, such as biohydrolyzable amides, biohydrolyzable esters, biohydrolyzable carbamates, biohydrolyzable carbonates, and biohydrolyzable phosphate analogs. Prodrugs are also described, for example, in The Practice of Medicinal Chemistry (Camille Wermuth, ed., 1999, Academic Press, which is incorporated herein by reference in its entirety). In certain embodiments, prodrugs of compounds having a carboxyl functional group are lower alkyl esters of the carboxylic acid. Carboxylic acid esters are conveniently formed by esterifying any of the carboxylic acid moieties present in the molecule. Prodrugs are typically prepared by known methods, for example, as described in Burger's Medicinal Chemistry and Drug Discovery 6 th ed. (Donald J. Abraham ed., 2001, Wiley) and Design and Application of Prodrugs(H.Bundgaard ed., 1985, Harwood Academic Publishers Gmfh, each of which is incorporated herein by reference in its entirety. The biohydrolyzable portion of the compound of formula I (a) does not interfere with the biological activity of the compound, but may confer advantageous properties to the compound in vivo, such as uptake, duration of action or onset of action; or (b) may be biologically inactive, but is converted in vivo to a biologically active compound. Examples of biohydrolyzable esters include, but are not limited to, lower alkyl esters, alkoxyacyloxyesters, alkylacylaminoalkyl esters, and choline esters. Examples of biohydrolyzable amides include, but are not limited to, lower alkyl amides, α-amino acid amides, alkoxyacyl amides, and alkylaminoalkylcarbonyl amides. Examples of biohydrolyzable carbamates include, but are not limited to, lower alkyl amines, substituted ethylenediamines, amino acids, hydroxyalkylamines, heterocyclic and heteroaromatic amines, and polyether amines.
[0422] The term "salt" includes salts derived from any suitable organic and inorganic counterions known in the art, such as hydrochloride or hydrobromide salts or alkali or acid salts of the aforementioned amino acids. The term is intended to include salts derived from inorganic or organic acids, including, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, perchloric acid, phosphoric acid, formic acid, acetic acid, lactic acid, maleic acid, fumaric acid, succinic acid, tartaric acid, glycolic acid, salicylic acid, citric acid, methanesulfonic acid, benzenesulfonic acid, benzoic acid, malonic acid, trifluoroacetic acid, trichloroacetic acid, naphthalene-2 sulfonic acid, and other acids; and salts derived from inorganic or organic bases, including, for example, sodium, potassium, calcium, ammonium, or tetrafluoroborate salts. Exemplary pharmaceutically acceptable salts include, for example, B erge et al. (J. Pharm. Sci. 1977, 66(1), 1; and U.S. Pat. Nos. 6,570,013 and 4,939,140, each of which is incorporated herein by reference in its entirety. Pharmaceutically acceptable salts are also intended to encompass hemi-salts in which the ratio of compound:acid is 2:1, respectively. Exemplary hemi-salts are salts derived from acids containing two carboxylic acid groups, such as malic acid, fumaric acid, maleic acid, succinic acid, tartaric acid, glutaric acid, oxalic acid, adipic acid, and citric acid. Other exemplary hemi-salts are salts derived from diproton mineral acids, such as sulfuric acid. Exemplary preferred hemi-salts include, but are not limited to, hemi-maleates, hemifumarates, and hemi-succinates.
[0423] The term "acid" contemplates all pharma- ceutically acceptable inorganic or organic acids. Inorganic acids include mineral acids, such as hydrohalic acids, e.g., hydrobromic and hydrochloric acids, sulfuric acid, phosphoric acid, and nitric acid. Organic acids include all pharma-ceutically acceptable aliphatic, alicyclic, and aromatic carboxylic acids, dicarboxylic acids, tricarboxylic acids, and fatty acids. Preferred acids are linear or branched, saturated or unsaturated C1-C carboxylic acids, optionally substituted with halogen or hydroxyl groups. 20 Aliphatic carboxylic acids, or C6-C 12 Aromatic carboxylic acids. Examples of such acids are carbonic acid, formic acid, fumaric acid, acetic acid, propionic acid, isopropionic acid, valeric acid, alpha-hydroxy acids such as glycolic acid and lactic acid, chloroacetic acid, benzoic acid, methanesulfonic acid and salicylic acid. Examples of dicarboxylic acids include oxalic acid, malic acid, succinic acid, tartaric acid and maleic acid. An example of a tricarboxylic acid is citric acid. Fatty acids include all pharma- ceutically acceptable saturated or unsaturated aliphatic or aromatic carboxylic acids having 4 to 24 carbon atoms. Examples include butyric acid, isobutyric acid, sec-butyric acid, lauric acid, palmitic acid, stearic acid, oleic acid, linoleic acid, linolenic acid and phenylsteric acid. Other acids include gluconic acid, glycoheptonic acid and lactobionic acid. III. Composition
[0424] The compound may be administered in the form of a suitable composition, such as a pharmaceutical composition. A pharmaceutical composition is physiologically acceptable and typically includes an active compound and a carrier. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the compound is administered. Non-limiting examples of such pharmaceutical carriers include liquids, such as water and oils, including those of petroleum, animal, vegetable, or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, and the like. The pharmaceutical carrier may also be saline, gum acacia, gelatin, starch paste, talc, keratin, colloidal silica, urea, and the like. In addition, auxiliary agents, stabilizers, thickeners, lubricants, and coloring agents may be used. Other examples of suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences (Alfonso Gennaro ed., Krieger Publishing Company (1997); Remington's: The Science and Practice of Pharmacy, 21 st Ed. (Lippincot, Williams & Wilkins (2005); Modern Pharmaceutics, vol. 121 (Gilbert Banker and Christopher Rhodes, CRC Press (2002), each of which is incorporated herein by reference in its entirety. In particular, the carrier may be suitable for ophthalmic application, e.g., application to the eye, for the treatment of ophthalmic diseases, e.g., cataracts. In another embodiment, the carrier may comprise a suppository for vaginal administration, e.g., for the treatment of premature ovarian insufficiency (POI).
[0425] The composition may be in any desired physiologically and / or pharma- ceutically acceptable form, such as a tablet, capsule, solution, emulsion, suspension, gel, sol or colloid. Optionally, the carrier may be, for example, a buffer, such as an alkaline buffer, for example an ammonium buffer. , acidic buffers such as ethanoate, citrate, lactate, acetate, and the like, or zwitterionic buffers such as glycine, alanine, valine, leucine, isoleucine, and phenylalanine, Krebs-Ringer buffer, TRIS, MES, ADA, ACES, PIPES, MOPSO, coramine chloride, MOPS, BES, TES, HEPES, DIPSO, MOBS, TAPSO, acetamidoglycine, TEA, POPSO, HEPPSO, EPS, HEPPS, tricine, TRIZMA, glycinamide, glycyl-glycine, HEPBS, bicine, TAPS, AMPB, CHES, AMP, AMPSO, CAPSO, CAPS, and CABS.
[0426] In the embodiment where the composition is in liquid form, the carrier can be a solvent or dispersion medium, including, but not limited to, water, ethanol, polyol (e.g., glycerol, propylene glycol, liquid polyethylene glycol, etc.), lipid (e.g., triglyceride, vegetable oil, liposome), and combinations thereof. The appropriate fluidity can be maintained, for example, by using a coating such as lecithin; by maintaining the required particle size by dispersing in a carrier such as liquid polyol or lipid; by using a surfactant such as hydroxypropylcellulose; or by a combination of such methods. If desired, a tonicity adjuster can be included, for example, sugar, sodium chloride, or a combination thereof. In some embodiments, the composition is isotonic.
[0427] The compositions may also include additional ingredients, such as acceptable surfactants, cosolvents, emollients, agents to adjust pH and osmolality, and / or antioxidants to retard oxidation of one or more components.
[0428] The composition can be prepared for administration by any suitable route, such as ocular (including periocular and intravitreal), oral, parenteral, intranasal, anal, intravaginal, topical, subcutaneous, intravenous, intraarterial, intrathecal and intraperitoneal.As shown in the examples disclosed herein, oral administration of aldose reductase inhibitors effectively reduces and normalizes galactitol levels in blood and tissues (including brain).Thus, it is generally preferred not to administer aldose reductase inhibitors intrathecally, although intrathecal administration is optional and can be selected by clinicians (e.g., when the aldose reductase inhibitor is not a central nervous system penetrant).For ocular administration, the composition can be formulated as, for example, drops, solutions, suspensions, emulsions, ointments, sustained release formulations, troches, elixirs, syrups, wafers, powders or combinations thereof. See Gaudana et al., AAPS J., 12(3):348-360, 2010. Oral compositions can be directly incorporated into dietary food. Preferred carriers for oral administration include inert diluents, edible carriers or combinations thereof. Examples of pharma-ceutically acceptable carriers can include, for example, water or saline, polymers such as polyethylene glycol, carbohydrates and their derivatives, oils, fatty acids or alcohols. Surfactants such as detergents are also suitable for use in the formulation.Specific examples of surfactants include polyvinylpyrrolidone, polyvinyl alcohol, copolymers of vinyl acetate and vinylpyrrolidone, polyethylene glycol, benzyl alcohol, mannitol, glycerol, polyoxyethylated esters of sorbitol or sorbitan; lecithin or sodium carboxymethylcellulose; or acrylic derivatives, such as methacrylates; anionic surfactants, such as alkaline stearates, in particular sodium stearate, potassium stearate or ammonium stearate; calcium stearate or triethanolamine stearate; alkyl sulfates, in particular sodium lauryl sulfate and sodium cetyl sulfate; sodium dodecylbenzenesulfonate or sodium dioctyl sulfosuccinate; or fatty acids, in particular those derived from coconut oil; cationic surfactants, such as water-soluble quaternary ammonium salts of the formula NR'R"R'"R""Y", where the R radicals are the same or different, optionally hydroxylated. are different hydrocarbon radicals and Y" is an anion of a strong acid, such as halides, sulfates and sulfonates; cetyltrimethylammonium bromide, which is one of the cationic surfactants that may be used, the amine salts of NR'R'R", where the R radicals are the same or different hydrocarbon radicals, optionally hydroxylated; octadecylamine hydrochloride, which is one of the cationic surfactants that may be used, nonionic surfactants, such as the optionally polyoxyethylated esters of sorbitan, in particular polysorbate 80 or polyoxyethylated alkyl ethers; polyethylene glycol stearates, polyoxyethylated derivatives of castor oil, polyglycerol esters, polyoxyethylated fatty alcohols, polyoxyethylated fatty acids or copolymers of ethylene oxide and propylene oxide, amphoteric surfactants, such as substituted lauryl compounds of betaine.
[0429] Optionally, oral composition can comprise one or more binders, excipients, disintegrants, lubricants, flavorings and their combinations.In certain embodiments, composition can comprise one or more of the following: binders, such as gum tragacanth, acacia, corn starch, gelatin or their combinations; excipients, such as dicalcium phosphate, mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, magnesium carbonate or their combinations; disintegrants, such as corn starch, potato starch, alginic acid or their combinations; lubricants, such as magnesium stearate; sweeteners, such as sucrose, lactose, saccharin or their combinations; flavorings, such as peppermint, wintergreen oil, cherry flavor, orange flavor, or their combinations containing two or more of the above.
[0430] Additional formulations suitable for other modes of administration include suppositories. Sterile injectable solutions may also be prepared using appropriate solvents. Generally, dispersions are prepared by incorporating the various sterile amino acid components into a sterile vehicle containing the basic dispersion medium and / or the other ingredients. Appropriate formulation methods for any desired mode of administration are well known in the art (generally, see Remington's Pharmaceutical Sciences, 18 th (See Ed. Mack Printing Company, 1990).
[0431] A typical pharma- ceutically acceptable composition may contain the AR inhibitor and / or its pharma- ceutically acceptable salt at a concentration ranging from about 0.01 to about 2 wt%, e.g., 0.01 to about 1 wt% or about 0.05 to about 0.5 wt%. The composition may be formulated as a solution, suspension, ointment, capsule, or the like. The pharmaceutical composition may be prepared as an aqueous solution and may contain additional components, such as preservatives, buffers, isotonicity agents, antioxidants, stabilizers, viscosity-adjusting components, and the like. Other equivalent modes of administration may be found in U.S. Pat. No. 4,939,140.
[0432] When administered to subject, AR inhibitor and pharmaceutically acceptable carrier can be sterile.Suitable pharmaceutical carrier can also contain excipient such as starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, skimmed milk powder, glycerol, propylene, glycol, propylene glycol 300, water, ethanol, polysorbate 20, etc.The present composition can contain a small amount of wetting agent or emulsifier or pH buffer if desired.
[0433] The pharmaceutical formulations of the present disclosure are prepared by methods well known in the art of pharmacy. If desired, one or more accessory ingredients (e.g., buffers, flavoring agents, surface active agents, etc.) may also be added. The choice of carrier will depend on the solubility and chemical properties of the compound, the chosen route of administration and standard pharmaceutical practice. The decision is made.
[0434] In some embodiments, the composition is in unit dosage form, such as a tablet, capsule, or single-dose vial. The appropriate unit dose, i.e., the therapeutically effective amount, can be determined during appropriately designed clinical trials for each condition in which administration of the selected compound is indicated, and will, of course, vary depending on the desired clinical endpoint.
[0435] Any of the compounds and / or compositions of the present disclosure may be provided in a kit that includes the compound and / or composition.Thus, in one embodiment, the compounds and / or compositions of the present disclosure are provided in a kit that includes a carrier and, optionally, instructions for using the kit for therapeutic or prophylactic use, in the same package or in separate packages. IV. Combination Therapy
[0436] The methods described herein include the administration of AR inhibitor and one or more additional therapeutic agents.Additional therapeutic agents can be administered before, at the same time, or after AR inhibitor, but in a manner that provides the overlap of pharmacological activity of AR inhibitor and additional therapeutic agents.Additional therapeutic agents can be, for example, a second aldose reductase inhibitor, an antioxidant, or both.
[0437] For example, a second aldose reductase can be synthesized by the methods described, for example, in U.S. Pat. No. 5,677,342; U.S. Pat. No. 5,155,259; U.S. Pat. No. 4,939,140; U.S. Patent Application Publication No. 2006 / 0293265; and Roy et al. (Diabetes Research and Clinical Practice, 10, Issue 1,91-97,1990; and the references cited therein (each of which is incorporated herein by reference in its entirety).Aldose reductase inhibitors include, for example, zopolrestat, epalrestat, ranirestat, berberine and sorbinil, as described in, for example, U.S. Pat. No. 4,939,140; U.S. Pat. No. 6,159,976; and U.S. Pat. No. 6,570,013.Preferably, the second aldose reductase inhibitor is selected from ponalrestat, epalrestat, sorbinil or sorbinol, imirestat, AND-138, CT-112, zopolrestat, zenarestat, BAL-AR18, AD-5467, M-79175, tolrestat, alkonyl, statyl, berberine or SPR-210.
[0438] Other therapeutic agents that may be administered include, for example, corticosteroids such as prednisone, methylprednisolone, dexamethasone, or triamcinalone acetinide, or noncorticosteroid anti-inflammatory compounds such as ibuprofen or flurbiprobe. Similarly, vitamins and minerals, such as zinc and micronutrients, may be co-administered. In addition, inhibitors of the protein tyrosine kinase pathway, including natural protein tyrosine kinase inhibitors such as quercetin, lavendustin A, erbstatin, and herbimycin A, and synthetic protein tyrosine kinase inhibitors such as tyrphostins (e.g., AG490, AG17, AG213 (RG50864), AG18, AG82, AG494, AG825, AG879, AG1112, AG1296, AG1478, AG126, RG13022, RG14620, and AG555), dihydroxy- and dimethoxybenzylidene malononitriles, analogs of lavendustin A (e.g., AG814 and AG957), quinazolines (e.g., AG1478), 4,5-dianilinophthalimides, and thiazolidinediones may be co-administered with genistein or an analog, prodrug, or pharma- ceutically acceptable salt thereof (Levitzki et al., Science 267:1782-1788 (1995); and Cunningham et al., Anti- (See Cancer Drug Design 7:365-384 (1992)). In this regard, potentially useful derivatives of genistein include those described in U.S. Patent No. 5,637,703 to Mazurek et al. Selenoindoles (2-thioindoles) and related disulfide selenides, such as those described in U.S. Patent No. 5,464,961 to Dobrusin et al., are useful protein tyrosine kinase inhibitors. Neutralizing proteins against growth factors, such as monoclonal antibodies specific for a given growth factor, e.g., VEGF (see, e.g., Aiello et al., PNAS USA 92:10457-10461 (1995)) or phosphotyrosine (Dhar et al., Mol. Pharmacol. 37:519-525 (1990)), may be co-administered.Various other compounds that may be co-administered include inhibitors of protein kinase C (see, e.g., U.S. Pat. Nos. 5,719,175 and 5,710,145), cytokine modulators, endothelial cell specific inhibitors of proliferation such as thrombospondin, endothelial cell specific inhibitory growth factors such as TNFα, antiproliferative peptides such as SPARC and proferin-like peptides, glutamate receptor antagonists, aminoguanidines, angiotensin converting enzyme inhibitors such as angiotensin II, calcium channel blockers, y-tectorigenin, ST638, somatostatin analogs such as SMS 201-995, monosialoganglioside GM1, ticlopidine, neurotrophic growth factors, methyl-2,5-dihydroxycinnamate, angiogenesis inhibitors such as recombinant EPO, sulfonylurea oral hypoglycemic agents such as gliclazide (non-insulin dependent diabetes mellitus), ST638 (Asahi et al., FEBS Letter 309:10-14 (1992)), thalidomide, nicardipine hydrochloride, aspirin, piceatannol, staurosporine, adriamycin, epidelstatin, (+)-aeroprisinin-1, phenazocine, halomethyl ketones, antilipidemic agents such as etofibrate, chlorpromazine, spingosine, and retinoic acid and their analogs (Burke et al., Drugs of the Future 17(2):119-131 (1992); and Tomlinson et al., Pharmac. Ther. 54:151-194 (1992)). V. Diagnostic Uses
[0439] The present disclosure further relates to diagnosing or predicting the risk of developing galactosemia in a subject by measuring one or more biomarkers associated with galactosemia.In one embodiment, the biomarker associated with galactosemia is an increase in galactitol levels in a biological sample obtained from a subject.Diagnosis can be performed, for example, by detecting an increase in the level of sugar metabolites, such as galactose (e.g., galactitol) and / or glucose (e.g., sorbitol) metabolites, in biological samples, such as aqueous humor or vitreous humor of the eye, blood tissue, cerebrospinal fluid, urine, etc.
[0440] Tables 1 and 2 show the concentrations of galactose and its metabolites in plasma (or whole blood), red blood cells and / or urine samples of subjects with classic galactosemia (GALT deficiency) or severe GALK deficiency.
[0441] The present disclosure further relates to a method for combined diagnosis and therapeutic intervention of galactosemia, wherein the diagnosis of galactosemia is performed as described above by detecting one or more biomarkers in a sample obtained from a subject.If the subject is determined to have galactosemia or is considered to be at risk of developing galactosemia based on the result of the diagnosis, a composition comprising an aldose reductase inhibitor (ARI) is administered to the subject.Preferably, the ARI comprises a compound of the present disclosure or a composition comprising a compound of the present disclosure.
[0442] In certain embodiments, the present disclosure provides a method for treating galactosemia, comprising diagnosing a subject for galactosemia by detecting elevated plasma galactitol concentrations (e.g., >10 μM galactitol) and / or elevated urinary galactitol levels (e.g., >100 mmol galactitol per mole creatine); and administering to a galactosemia subject in need thereof a therapeutically effective amount of a composition that inhibits aldose reductase activity. In another embodiment, the diagnostic step may further comprise a genetic test, for example, detecting one or more mutations in the enzymes involved in the Leloir pathway (e.g., GALT, GALK, GALE, etc.). In yet another embodiment, the diagnostic step may further include performing an enzyme assay, e.g., an assay for GALT, GALK and / or GALE activity using a detectable substrate, the products of which may be detected using conventional methods, e.g., HPLC or mass spectrometry (Ko et al., Clinical Chemistry 56:5 764-771,2010).
[0443] The present disclosure further provides the use of a compound of Formula I-VI or a pharma- ceutically acceptable salt, hydrate, solvate or prodrug thereof in a method of treating a disease state and / or condition caused by or associated with galactosemia. In another embodiment, the present disclosure relates to the use of a compound of Formula I-VI or a pharma- ceutically acceptable salt, hydrate, solvate or prodrug thereof in a method of treating a disease state and / or condition caused by or associated with galactosemia, the method comprising the steps of: (a) identifying a subject in need of such treatment; (b) providing a compound of Formula I-VI or a pharma- ceutically acceptable salt, hydrate, solvate or prodrug thereof; and (c) administering said compound of Formula I-VI in a therapeutically effective amount to treat, inhibit and / or prevent the disease state or condition in the subject in need of such treatment.
[0444] In another embodiment, the present disclosure relates to the use of a compound of Formula I-VI or a pharma- ceutically acceptable salt, hydrate, solvate, or prodrug thereof in a method of treating a disease state and / or symptom caused by or associated with galactosemia, comprising the steps of: (a) identifying a subject in need of such treatment; (ii) providing a composition comprising a compound of Formula I-VI or a pharma- ceutically acceptable salt, hydrate, solvate, prodrug, or tautomer thereof; and (iii) administering the composition in a therapeutically effective amount to treat, inhibit, and / or prevent the disease state or symptom in the subject in need of such treatment.
[0445] In the foregoing embodiments, the compound or composition is preferably administered orally. EXAMPLES
[0446] It will be understood that the structures, materials, compositions, and methods described herein are intended to be representative examples of the disclosure, and that the scope of the disclosure is not limited by the scope of the examples. Those skilled in the art will recognize that the disclosure may be practiced using variations of the disclosed structures, materials, compositions, and methods, and that such variations are considered to be within the scope of the disclosure.
[0447] Rats with impaired GALT activity due to genetic modification (GALT null) were used as a model of galactosemia. This rat model reflects classical galactosemia in humans in several important respects. Rats develop physical features including cataracts, growth abnormalities and neurological / cognitive abnormalities following exposure to galactose that reflect and are quantifiable in human patients. Rats also have biochemical features that reflect the human disease, including elevated levels of galactose and galactose metabolites, including galactitol and Gal1, in blood and tissues.
[0448] Rats are fed a diet containing one or more aldose reductase inhibitors (ARIs), and the effect of AR inhibition is analyzed at the tissue level and even in vitro level. For example, the galactitol level of the eye of GALT-deficient rats can be measured before and after treatment with the ARIs disclosed herein. Alternatively or additionally, the effect of the ARI in reducing the frequency and severity of galactosemia and / or improving disease outcomes (e.g., improving visual ability, motor ability, or memory ability) is measured using conventional methods. Example 1
[0449] A study was conducted to examine the effect of aldose reductase inhibitors (ARIs) (Compound A or Compound B) in a rat model of classical galactosemia (GALT null rats). The effect of aldose reductase inhibitor treatment on key aspects of galactosemia, including growth, cataract formation, and metabolite levels (galactose and galactitol) in the liver, brain, and circulation of GALT null rats exposed to breast milk, was analyzed.
[0450] [ka] methodology
[0451] Genetic model: Rats were generated from heterozygous matings (heterozygous M3 GALT null strain exhibiting classical galactosemia). Wild-type (WT, + / +) and heterozygous rats (+ / M3) express normal levels of GALT, whereas M3 homozygotes (M3 / M3) do not express detectable levels of GALT and exhibit abnormally high levels of galactose and galactitol in the liver and brain.
[0452] Drug and placebo application: The vehicle used to administer drugs to the neonates was Gerber Good Start Birth-12 Months soy formula, prepared according to the manufacturer's instructions (157.5 mg of powder added to 1 ml of deionized water and mixed thoroughly before use). Liquid formula was prepared fresh daily from the powder and stored at 4° C. until use. Liquid formula alone (no drug powder added) served as the placebo control.
[0453] Aldose reductase inhibitors (Compound A or Compound B) suspended in Gerber formula were orally administered at approximately 12-hour intervals (BID) at 1 mg inhibitor / gram pup body weight (=1000 mg / kg) for each administration. Drugs were stored at -20°C in aluminum foil-wrapped bottles or tubes prior to use. Just prior to each feeding, an aliquot of drug was resuspended in formula, mixed thoroughly, pipetted into individual tubes, and fed to the pups (volumes were calculated according to the pups' weights measured that morning). Just prior to feeding, all placebo and drug tubes of formula were warmed to 37°C.
[0454] Placebo and drug were hand-fed to the pups using syringes and tubes. Drug-treated pups were fed an additional small amount of Gerber formula, which was used to clean the tubes and syringes immediately after drug feeding. To encourage feeding, pups were separated from their mothers (to prevent nursing) and kept in bedding in a humidified incubator at 35-37°C for approximately 2 hours before each feeding. Separate syringes were used for placebo and drug. Pups were wrapped in fleece during feedings, which lasted approximately 2-5 minutes each.
[0455] Growth monitoring: Growth was monitored by weighing each pup daily (in grams).
[0456] Cataract Tracking / Quantification: In the first part of the study, blinded assessors visually scored cataracts on a 3-point scale, with 0 being no cataract (absent), 1 being mild, 2 being moderate, and 3 being severe cataract present. In the second part of the study, after euthanasia, eyes were dissected, photographed with a digital camera, and cataracts were quantified by software.
[0457] Genotype determination: GALT genotype of pups (M3 / M3 vs. M3 / + vs. + / +) was determined by Transnetyx using DNA isolated from tail fragments collected from all pups at postnatal days 5-8. Genotype in representative pups was confirmed by GALT enzyme activity measured in liver samples taken from pups after euthanasia. In all samples tested, the observed GALT activity was consistent with GALT genotype.
[0458] Euthanasia of pups: Pups were euthanized by CO2 inhalation according to standard procedures.
[0459] Enzyme assays: as previously described (Sanders et al., Dis Model Mech.,3(9-10):628-38,2010), galactose-1-P uridyl transferase (GALT) and galactokinase (GALK) assays were performed using lysates prepared from frozen samples of liver. As a control for sample integrity, the GALK assay was performed. Lysates were prepared by homogenizing small pieces of liver (10-50 mg) in 100 μl of lysis buffer consisting of one Complete Mini Protease Inhibitor Cocktail tablet, EDTA-free (Roche, REF 04 693 159 001) dissolved in 10 ml of 100 mM glycine, pH 8.7. The lysates were centrifuged at 16,110 × g for 5 min at 4 °C, and the resulting supernatant was passed through a MICRO BIO-SPIN P-6 chromatography column (Bio-Rad, Inc.) to remove small molecules. Protein concentrations were determined for each sample using the BIO-RAD DC protein assay with BSA as a standard. GALT and GALK assays were performed using 4 μg of total protein per reaction. Substrates and products were quantified by HPLC as previously described (Ross, 2004).
[0460] Metabolites: Lysates for metabolite analysis were prepared as follows: 50-100 mg pieces of pre-frozen liver or brain were homogenized in 125 μl of ice-cold HPLC-grade water by grinding for 30 s using a Teflon micropestle and handheld micropestle motor (Kimble Chase Life Science and Research Products LLC). Metabolites were separated and quantified by HPLC (see, e.g., Daenzer et al., Dis. Model 2002). Mech. 2016,9(11):1375-1382). Galactitol, inositol and glucose were quantified using the same HPLC conditions described for galactose quantification by (Daenzer, 2016). Metabolite levels were normalized to the total peak area detected by the relevant column and elution run for that sample minus the peak that best differentiated the homozygous M3 / M3 sample from the control. Specifically, metabolites separated on the MA1 column (galactitol, inositol, galactose and glucose) were normalized to the total peak area minus galactose and galactitol, and the total peak area minus galactose and galactitol. The metabolites separated on the PA10 column (galactose-1P) were normalized to those subtracted by galactose-1P. result
[0461] Survival observations: The drug-containing formula was slightly "thicker" in viscosity than formula alone, but the pups consumed both with no apparent rejection.
[0462] Growth: Pups were weighed every morning and mass was recorded in grams. The mass of pups that continued to gain weight is shown in Figure 1. As shown, the weight of homozygous GALT null pups tended to lag behind their wild type and heterozygous GALT+ littermates, but the differences were small. Other studies have demonstrated that the delay becomes more pronounced and statistically significant after the third week of life.
[0463] The data presented in Figure 1 indicate that drug treatment can reduce or prevent growth retardation in homozygotes.
[0464] Cataracts: Cataracts are the most obvious visible phenotype associated with the GALT null state in the rat model. At postnatal day 14, rats open their eyes and bilateral cataracts are present. Of note, infants with classical galactosemia exposed to dietary galactose (e.g., breast milk) also develop bilateral cataracts. In the GALT null rat model, in the absence of therapeutic intervention, cataracts are seen in all M3 / M3 homozygous pups but not in M3 / + or + / + pups. In initial studies, cataracts were qualitatively assessed in GALT null rats treated with Compound A or placebo at postnatal day 9. The qualitative assessment was on a scale of 0 to 3, with 0 indicating the absence of cataracts and 3 indicating severe cataracts. As shown in Figure 2A, GALT null rats treated with placebo developed severe cataracts by postnatal day 9. In contrast, GALT null rats treated with Compound A did not have cataracts. Follow-up studies were performed in which rats were treated twice daily with 1,000 mg / kg or 250 mg / kg Compound A, the eyes were digitally photographed, and cataracts were quantified. In both studies, Compound A reduced cataracts.
[0465] Further studies were performed using Compound B to evaluate cataracts at 22 days of age. Qualitative assessment on a scale of 0 to 3 indicates that in this study, placebo-treated GALT null rats developed cataracts, with an average severity of 1.5, while wild-type and GALT null rats treated with Compound B did not have cataracts (Figure 2D). Digital quantitative analysis yielded the same results, with Compound B-treated GALT null rats having the same score as wild-type rats, while placebo-treated GALT null rats had a higher score indicative of cataracts (Figure 2B).
[0466] Since GALT null rats have cataracts when they open their eyes on postnatal day 14, it is possible that treatment of newborn rats with aldose reductase inhibitors can prevent the formation of cataracts after birth and / or reduce cataracts formed in utero. Further studies using compound B provided evidence that aldose reductase inhibitors can reduce cataracts that have already formed. In this study, cataracts were evaluated on postnatal days 10 and 22. As shown in Figure 2C and Figure 2D, on days 10 and 22, placebo-treated GALT null rats had cataracts. However, on day 10, compound B-treated GALT null rats had cataracts, but on day 22, cataracts were not present. The data demonstrate that treatment with aldose reductase inhibitors can reduce and eliminate cataracts.
[0467] Metabolites: HPLC analysis showed that both liver and brain samples from euthanized pups Galactose and galactitol metabolites were separated and quantified by ELISA. Treatment with Compound A reduced liver galactitol levels in GALT null rats by 87% on day 9 and by 57% on days 15-18 compared to placebo. Treatment with Compound A reduced brain galactitol levels in GALT null rats by 40% on day 9 and by 57% on days 15-18 compared to placebo. Further studies were performed in rats treated with Compound B to measure galactose and galactitol levels on postnatal day 10. Results of this study showed that GALT null rats had elevated levels of galactitol in liver, brain, and plasma compared to wild-type rats. Treatment with Compound B reduced galactitol levels in GALT null rats to normal or near-normal levels (Figure 3A). GALT null rats also had elevated galactose and Gal1P levels compared to wild-type rats. Treatment with Compound B did not further increase galactose or Gal1P levels in GALT null rats (Figures 3B and 3C). The data demonstrate that aldose reductase inhibitors can reduce and normalize galactitol levels in diseased animals, but do not further increase galactose and Gal1P levels. Conclusions and Discussion
[0468] This study examined the effects of aldose reductase inhibitor exposure (Compound A or Compound B) on growth, cataract formation, and galactitol accumulation in GALT null rat pups. As expected, breast milk-exposed GALT null animals accumulated dramatically elevated galactose and galactitol in both liver and brain compared to GALT+ heterozygotes or wild-type animals. Treatment with aldose reductase inhibitors significantly reduced galactitol in brain, liver, and blood (plasma). Treatment with aldose reductase inhibitors also had a dramatic effect on cataracts, demonstrating that aldose reductase inhibitors can reduce existing cataracts to the point where they are no longer present. These data demonstrate that aldose reductase inhibitors can be administered to effectively treat galactosemia. Example 2
[0469] This study studies the long-term cognitive and neurological dysfunction associated with galactosemia in GALT null rats and normal control rats treated with placebo or aldose reductase inhibitor.Aldose reductase inhibitor is administered as described in Example 1 substantially, and rats are evaluated for central nervous system outcomes using the rotarod test to evaluate balance, motor control and learning, and using the novel object recognition test to evaluate cognition and memory.In these tests, GALT null rats show altered responses compared to wild-type rats.The data show that treatment with aldose reductase inhibitor reduces the cognitive and neurological dysfunction of GALT null rats, and some or all of the responses of GALT null rats are normalized to those observed in wild-type rats. Example 3
[0470] A newborn is diagnosed with classical galactosemia by newborn screening and shows elevated blood galactose and galactitol levels. Immediately, the child is placed on a galactose- and lactose-restricted diet. Treatment with an aldose reductase inhibitor (e.g., Compound A or Compound B) is initiated at a dose selected by the clinician to normalize blood galactose and / or galactitol levels. Treatment results in a reduction and eventual normalization of blood galactitol levels. The child continues treatment indefinitely, with periodic testing to ensure that blood galactitol levels are normal. Dosing is adjusted, if necessary, to maintain normal blood galactitol levels. As the child gets older, There is no growth retardation, speech delay, learning disability, ataxia, or presenile cataracts. Example 4
[0471] Adult patients with galactosemia exhibit ataxia, spasticity and impaired balance. To normalize blood galactose and / or galactitol levels, treatment with an aldose reductase inhibitor (e.g., Compound A or Compound B) is initiated at a dose selected by the clinician. Treatment results in a reduction and eventual normalization of blood galactitol levels. As galactitol levels normalize, patients exhibit reduced ataxia and spasticity and improved balance. If necessary, dosage is adjusted to maintain normal blood galactitol levels and improved motor control and balance of the patient.
[0472] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs.
[0473] Methods and materials similar or equivalent to those described herein may be used in carrying out or testing this disclosure, and suitable methods and materials are described in the preceding paragraphs.In addition, materials, methods and examples are merely illustrative and are not intended to be limiting.All U.S. patents and published or unpublished U.S. patent applications cited herein are incorporated by reference.All published foreign patents and patent applications cited herein are incorporated by reference.All published references, documents, manuscripts, and scientific literature cited herein are incorporated by reference.All identifiers and accession numbers for scientific databases (e.g., PUBMED, NCBI, GENBANK, EBI) referenced herein are incorporated by reference.
[0474] According to a preferred embodiment of the present invention, for example, the following is provided: (Section 1) 2. A method of treating galactosemia or preventing complications associated with galactosemia, comprising administering to a subject in need thereof a therapeutically effective amount of an aldose reductase inhibitor. (Section 2) A method for reducing the amount or level of galactitol in a subject having galactosemia, comprising administering to the subject a therapeutically effective amount of an aldose reductase inhibitor. (Section 3) SUMMARY OF THE DISCLOSURE A method for treating cataracts, comprising administering to a subject in need thereof a therapeutically effective amount of an aldose reductase inhibitor. (Section 4) The method according to paragraph 3 above, wherein the subject in need thereof has galactosemia. (Section 5) 1. A method for treating or preventing cognitive or neurological dysfunction associated with galactosemia, comprising administering to a subject having galactosemia a therapeutically effective amount of an aldose reductase inhibitor. (Section 6) 6. The method according to item 5, wherein the cognitive or neurological dysfunction associated with galactosemia is a speech dysfunction. (Section 7) 6. The method according to item 5, wherein the cognitive or neurological dysfunction associated with galactosemia is ataxia. (Section 8) 6. The method according to item 5, wherein the cognitive or neurological dysfunction associated with galactosemia is cognitive dysfunction. (Section 9) 6. The method according to item 5, wherein the cognitive or neurological dysfunction associated with galactosemia is pseudotumor cerebri. (Section 10) 6. The method according to item 5, wherein the cognitive or neurological dysfunction associated with galactosemia is convulsion. (Section 11) 11. The method according to any one of items 1 to 10, wherein the aldose reductase inhibitor is a compound of any one of formulae I to VI or a salt thereof. (Section 12) 11. The method according to any one of items 1 to 10, wherein the aldose reductase inhibitor is zopolrestat or a salt thereof, or epalrestat or a salt thereof. (Section 13) 11. The method according to any one of items 1 to 10, wherein the aldose reductase inhibitor is a compound of formula (II) or a salt thereof. (Section 14) The aldose reductase inhibitor is [ka] 14. The method according to item 13 above, wherein the compound is selected from the group consisting of aryl, arylamino, arylpropanediol, arylsulfate, arylsulfuric acid ... (Section 15) 11. The method according to any one of items 1 to 10, wherein the aldose reductase inhibitor is a compound of formula III. (Section 16) The aldose reductase inhibitor is [ka] 16. The method according to item 15 above, wherein the compound is selected from the group consisting of aryl, arylamino, arylpropionic acid ... (Section 17) 17. The method according to any one of items 1 to 16, wherein the subject is a human. (Section 18) 18. The method according to any one of items 1 to 17, wherein the galactosemia is manifested in the subject as increased alditol levels in blood, urine, or intraocular fluid. (Section 19) 19. The method according to claim 18, wherein the alditol is galactitol, myo-inositol or sorbitol. (Section 20) 20. The method according to any one of items 1 to 19, wherein the galactosemia is manifested in the subject as increased liver cirrhosis, retinopathy, macular edema, eye cataracts, ovarian dysfunction, muscle or nerve dysfunction, retinopathy, neuropathy, nerve conduction disorders or mental retardation. (Section 21) 21. The method according to any one of items 1 to 20 above, wherein the galactosemia is type I galactosemia (GALT deficiency). (Section 22) 21. The method according to any one of items 1 to 20 above, wherein the galactosemia is type II galactosemia (GALK deficiency). (Section 23) 11. The method according to any one of items 1 to 10, wherein the galactosemia is type III galactosemia (GALE deficiency). (Section 24) The method according to any one of the preceding clauses, wherein the aldose reductase inhibitor is compound A or a salt thereof. (Section 25) The method according to any one of the preceding clauses, wherein the aldose reductase inhibitor is compound B or a salt thereof.
Claims
[Claim 1] Galactosemia.
